


**CUMULATIVE
SUPPLEMENT 2
FEBRUARY 2018**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2018

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**Cumulative Supplement 2
February 2018**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

38th EDITION

CUMULATIVE SUPPLEMENT 2
February 2018

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
SAGENT AGILA LLIC (SAGENT AGILA)	MYLAN ASI LLC (MYLAN ASI)
SAGENT AGILA LLC (SAGENT AGILA LLC)	MYLAN ASI LLC (MYLAN ASI)
SAGENT STRIDES LLC (SAGENT STRIDESC)	MYLAN ASI LLC (MYLAN ASI)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference

listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange

Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts,

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2017</u>	<u>MAR 2018</u>	<u>JUN 2018</u>	<u>SEP 2018</u>	<u>DEC 2018</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	19294				
	2758				
	(14.3%)				
MULTISOURCE	16536				
	(85.7%)				
THERAPEUTICALLY EQUIVALENT	16431				
	(85.2%)				
NOT THERAPEUTICALLY EQUIVALENT	105				
	(0.5%)				
EXCEPTIONS ¹	73				
	(0.4%)				
NEW MOLECULAR ENTITIES APPROVED	25				
NUMBER OF APPLICANTS	1075				

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL
 ABACAVIR SULFATE

>A> AA AUROBINDO PHARMA LTD EQ 20MG BASE/ML A 077950 001 Mar 14, 2018 Feb NEWA

ABIRATERONE ACETATE

TABLET;ORAL
 ZYTIGA

>D> +! JANSSEN BIOTECH 250MG N202379 001 Apr 28, 2011 Feb CHRS
 >A> + 250MG N202379 001 Apr 28, 2011 Feb CHRS
 >D> + 500MG N202379 002 Apr 14, 2017 Feb CHRS
 >A> +! 500MG N202379 002 Apr 14, 2017 Feb CHRS

>A> ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
 APADAZ

>A> + KEMPHARM 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
 ACETAMINOPHEN AND CODEINE PHOSPHATE
 @ FOSUN PHARMA 300MG;30MG
 @ 300MG;60MG

A 081250 001 Jul 16, 1992 Jan CAHN
 A 081249 001 Jul 16, 1992 Jan CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL
 OXYCODONE AND ACETAMINOPHEN
 @ SPECGX LLC 325MG/5ML;5MG/5ML
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN
 @ VINTAGE PHARMS 325MG/5ML;5MG/5ML

A 040680 001 Sep 29, 2006 Jan DISC
 A 203573 001 Dec 18, 2014 Jan DISC

TABLET;ORAL
 OXYCODONE AND ACETAMINOPHEN

AA ABHAI LLC 325MG;2.5MG A210644 001 Feb 09, 2018 Jan NEWA
 AA 325MG;5MG A210644 002 Feb 09, 2018 Jan NEWA
 AA 325MG;7.5MG A210644 003 Feb 09, 2018 Jan NEWA
 AA 325MG;10MG A210644 004 Feb 09, 2018 Jan NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC
 ACETIC ACID

>A> AT RISING PHARMS INC 2% A207280 001 Mar 09, 2018 Feb NEWA

ACYCLOVIR

TABLET;ORAL
 ACYCLOVIR

>A> AB YILING PHARM LTD 400MG A210401 001 Mar 07, 2018 Feb NEWA
 >A> AB 800MG A210401 002 Mar 07, 2018 Feb NEWA

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL
 ADAPALENE AND BENZOYL PEROXIDE

AB PERRIGO ISRAEL 0.1%;2.5% A205033 001 Jan 23, 2018 Jan NEWA
 AB TARO 0.1%;2.5% A206959 001 Jan 24, 2018 Jan NEWA

ADENOSINE

INJECTABLE;INJECTION
 ADENOSINE

>A> AP GLAND PHARMA LTD 3MG/ML A206778 001 Feb 16, 2018 Feb NEWA

ALBUTEROL SULFATE

TABLET;ORAL
 ALBUTEROL SULFATE
 @ YAOPHARMA CO LTD EQ 2MG BASE
 @ EQ 4MG BASE

A 072151 001 Dec 05, 1989 Jan CAHN
 A 072152 001 Dec 05, 1989 Jan CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ FOSUN PHARMA EQ 0.083% BASE; 0.017% A076867 001 Dec 21, 2006 Jan CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB HANGZHOU BINJIANG EQ 5MG BASE A090258 001 Sep 24, 2009 Jan CAHN
 AB EQ 10MG BASE A090258 002 Sep 24, 2009 Jan CAHN
 AB EQ 35MG BASE A090258 003 Sep 24, 2009 Jan CAHN
 AB EQ 70MG BASE A090258 004 Sep 24, 2009 Jan CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

@ FOSUN PHARMA 100MG A070268 001 Dec 31, 1985 Jan CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

>A> AB PAR PHARM INC EQ 0.5MG BASE A206113 001 Feb 23, 2018 Feb NEWA
 >A> AB EQ 1MG BASE A206113 002 Feb 23, 2018 Feb NEWA

AMANTADINE HYDROCHLORIDE

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB JUBILANT GENERICS 100MG A210403 001 Feb 07, 2018 Jan NEWA
 >A> TABLET, EXTENDED RELEASE; ORAL
 >A> OSMOLEX ER
 >A> + OSMOTICA PHARM EQ 129MG BASE N209410 001 Feb 16, 2018 Feb NEWA
 >A> + EQ 193MG BASE N209410 002 Feb 16, 2018 Feb NEWA
 >A> +! EQ 258MG BASE N209410 003 Feb 16, 2018 Feb NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ YAOPHARMA CO LTD EQ 5MG ANHYDROUS; 50MG A073357 001 Nov 27, 1991 Jan CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB SUN PHARM INDS INC 10MG A089399 002 Jul 14, 1987 Jan CMFD
 AB 25MG A089399 001 Jul 14, 1987 Jan CMFD
 AB 50MG A089399 003 Jul 14, 1987 Jan CMFD
 AB 75MG A089399 004 Jul 14, 1987 Jan CMFD
 AB 100MG A089399 005 Jul 14, 1987 Jan CMFD
 AB 150MG A089399 006 Jul 14, 1987 Jan CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@ FOSUN PHARMA 10MG; 2MG A071062 001 Nov 27, 1987 Jan CAHN
 @ 10MG; 4MG A071862 001 Dec 21, 1987 Jan CAHN
 @ 25MG; 4MG A071064 001 Nov 27, 1987 Jan CAHN
 @ 50MG; 4MG A071863 001 Dec 21, 1987 Jan CAHN
 @ SANDOZ INC 25MG; 2MG A071063 001 Nov 27, 1987 Jan CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

@ YAOPHARMA CO LTD EQ 2.5MG BASE A076859 001 Sep 10, 2007 Jan CAHN
 @ EQ 5MG BASE A076859 002 Sep 10, 2007 Jan CAHN
 @ EQ 10MG BASE A076859 003 Sep 10, 2007 Jan CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>D> AP IBA MOLECULAR N AM 18.8mCi-188mCi/5ML (3.75-37.5mCi/ML) A204667 001 Apr 22, 2015 Feb CAHN
 >A> AP SOFIE 18.8mCi-188mCi/5ML (3.75-37.5 A204667 001 Apr 22, 2015 Feb CAHN

INJECTABLE; INTRAVENOUS
AMMONIA N 13

mCi/ML)

AMMONIUM LACTATE

CREAM; TOPICAL
LAC-HYDRIN

>D> @ RANBAXY EQ 12% BASE N020508 001 Aug 29, 1996 Feb CAHN
>A> @ SUN PHARM INDS INC EQ 12% BASE N020508 001 Aug 29, 1996 Feb CAHN

LOTION; TOPICAL
LAC-HYDRIN

>D> + @ RANBAXY EQ 12% BASE N019155 001 Apr 24, 1985 Feb CAHN
>A> + @ SUN PHARM INDS INC EQ 12% BASE N019155 001 Apr 24, 1985 Feb CAHN

ANASTROZOLE

TABLET; ORAL
ARIMIDEX

AB +! ANI PHARMS INC 1MG N020541 001 Dec 27, 1995 Jan CAHN

ANGIOTENSIN II ACETATE

SOLUTION; IV (INFUSION)
GIAPREZA

+! LA JOLLA PHARM CO EQ 2.5MG BASE/ML (EQ 2.5MG N209360 001 Dec 21, 2017 Jan CAIN
BASE/ML)
+! EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) N209360 002 Dec 21, 2017 Jan CAIN

>A> APALUTAMIDE

>A> TABLET; ORAL
>A> ERLEADA

>A> +! JANSSEN BIOTECH 60MG N210951 001 Feb 14, 2018 Feb NEWA

APREPITANT

CAPSULE; ORAL
APREPITANT

AB GLENMARK PHARMS SA 40MG A207777 001 Oct 12, 2017 Jan CAHN
AB 80MG A207777 002 Oct 12, 2017 Jan CAHN
AB 125MG A207777 003 Oct 12, 2017 Jan CAHN

ARGATROBAN

INJECTABLE; INJECTION
ARGATROBAN

AP AMNEAL PHARMS CO 250MG/2.5ML (100MG/ML) A206698 001 Jan 26, 2018 Jan NEWA

ARMODAFINIL

TABLET; ORAL
ARMODAFINIL

>A> AB AUROBINDO PHARMA LTD 50MG A206069 001 Mar 06, 2018 Feb NEWA
>A> AB 150MG A206069 002 Mar 06, 2018 Feb NEWA
>A> AB 250MG A206069 003 Mar 06, 2018 Feb NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

@ FOSUN PHARMA 325MG; 50MG; 40MG A086398 002 Apr 06, 1984 Jan CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENGESIC

>A> @ GALT PHARMS 385MG; 30MG; 25MG A075141 001 May 29, 1998 Feb CAHN
>D> @ PRINSTON INC 385MG; 30MG; 25MG A075141 001 May 29, 1998 Feb CAHN

ORPHENGESIC FORTE

>A> @ GALT PHARMS 770MG; 60MG; 50MG A075141 002 May 29, 1998 Feb CAHN
>D> @ PRINSTON INC 770MG; 60MG; 50MG A075141 002 May 29, 1998 Feb CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL AND ASPIRIN

@ OXFORD PHARMS 325MG; 200MG A040252 001 Dec 10, 1997 Jan DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

>A>	AB	DR REDDYS LABS LTD	10MG	A090609	001	Feb 23, 2018	Feb	NEWA
>A>	AB		18MG	A090609	002	Feb 23, 2018	Feb	NEWA
>A>	AB		25MG	A090609	003	Feb 23, 2018	Feb	NEWA
>A>	AB		40MG	A090609	004	Feb 23, 2018	Feb	NEWA
>A>	AB		60MG	A090609	005	Feb 23, 2018	Feb	NEWA
>A>	AB		80MG	A090609	006	Feb 23, 2018	Feb	NEWA
>A>	AB		100MG	A090609	007	Feb 23, 2018	Feb	NEWA

ATROPINE SULFATE

SOLUTION;IV (INFUSION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+! FRESENIUS KABI USA 8MG/20ML (0.4MG/ML)

N209260 001 Jan 26, 2018 Jan NEWA

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

>A>		ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Feb	CAHN
>D>		NOVARTIS PHARMS CORP	1%	N208151	001	Dec 01, 2016	Feb	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ FOSUN PHARMA 0.025MG;2.5MG

A086173 001 Jan CAHN

LONOX

@ FOSUN PHARMA 0.025MG;2.5MG

A085311 002 Jan CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+! ALLERGAN SALES LLC EQ 0.5GM BASE;2GM/VIAL

N206494 001 Feb 25, 2015 Jan CAHN

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

@ MYLAN ASI 50,000 UNITS/VIAL

A090211 001 May 11, 2010 Jan DISC

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

>A>	AP	MYLAN LABS LTD	1MG/ML	A209594	001	Mar 06, 2018	Feb	NEWA
-----	----	----------------	--------	---------	-----	--------------	-----	------

GABLOFEN

>D>		+! PIRAMAL CRITICAL	1MG/ML	N022462	004	Jun 22, 2012	Feb	CFTG
-----	--	---------------------	--------	---------	-----	--------------	-----	------

>A>	AP	+!	1MG/ML	N022462	004	Jun 22, 2012	Feb	CFTG
-----	----	----	--------	---------	-----	--------------	-----	------

BARIUM SULFATE

SUSPENSION;ORAL

VARIBAR THIN HONEY

+! BRACCO 40% (100GM/250ML)

N208143 006 Jan 23, 2018 Jan NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR REDIHALER

+! NORTON WATERFORD 0.04MG/INH

N207921 001 Aug 03, 2017 Jan CHRS

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

@ CHARTWELL RX 1MG

A081264 001 Jan 23, 1992 Jan CAHN

@ 2MG

A081265 001 Jan 23, 1992 Jan CAHN

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		HI-TECH PHARMACAL	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Jan	NEWA
----	--	-------------------	---------------	---------	-----	--------------	-----	------

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		TELGENT PHARMA INC	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Jan	NEWA
----	--	--------------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATELOTION;TOPICAL
BETA-VAL

@ G AND W LABS INC EQ 0.1% BASE A070072 001 Jun 27, 1985 Jan DISC

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETOPTIC

AT +! SANDOZ INC EQ 0.5% BASE N019270 001 Aug 30, 1985 Jan CAHN

BICALUTAMIDETABLET;ORAL
CASODEX

AB +! ANI PHARMS INC 50MG N020498 001 Oct 04, 1995 Jan CAHN

>A> BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

>A> TABLET;ORAL

>A> BIKTARVY

>A> +! GILEAD SCIENCES INC EQ 50MG BASE;200MG;EQ 25MG BASE N210251 001 Feb 07, 2018 Feb NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE;ORAL
PYLERA

+! ALLERGAN SALES LLC 140MG;125MG;125MG N050786 001 Sep 28, 2006 Jan CAHN

BIVALIRUDINSOLUTION;IV (INFUSION)
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP 250MG/50ML (5MG/ML) N208374 001 Dec 21, 2017 Jan CAHN

+! 500MG/100ML (5MG/ML) N208374 002 Dec 21, 2017 Jan CAHN

BUMETANIDETABLET;ORAL
BUMETANIDE

AB UPSHER-SMITH LABS 0.5MG A209916 001 Jan 23, 2018 Jan NEWA

AB 1MG A209916 002 Jan 23, 2018 Jan NEWA

AB 2MG A209916 003 Jan 23, 2018 Jan NEWA

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB2 SCIEGEN PHARMS INC 150MG A206122 001 Aug 17, 2016 Jan CAHN

BUSPIRONE HYDROCHLORIDETABLET;ORAL
BUSPIRONE HYDROCHLORIDE

>A> AB AUROBINDO PHARMA LTD 5MG A078246 001 Feb 27, 2009 Feb CAHN

>A> AB 10MG A078246 002 Feb 27, 2009 Feb CAHN

>A> AB 15MG A078246 003 Feb 27, 2009 Feb CAHN

>A> AB 30MG A078246 004 Feb 27, 2009 Feb CAHN

>D> AB DR REDDYS LABS LTD 5MG A078246 001 Feb 27, 2009 Feb CAHN

>D> AB 10MG A078246 002 Feb 27, 2009 Feb CAHN

>D> AB 15MG A078246 003 Feb 27, 2009 Feb CAHN

>D> AB 30MG A078246 004 Feb 27, 2009 Feb CAHN

@ FOSUN PHARMA 5MG A075413 001 Mar 19, 2002 Jan CAHN

@ 10MG A075413 002 Mar 19, 2002 Jan CAHN

@ 15MG A075413 003 Mar 19, 2002 Jan CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;104MG/100ML;6 00MG/100ML;310MG/100ML N019685 005 Oct 17, 1988 Jan CRLD

+ @ 20MG/100ML;5GM/100ML;179MG/100ML;6 00MG/100ML;310MG/100ML N019685 006 Oct 17, 1988 Jan CRLD

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;254MG/100ML;6 00MG/100ML;310MG/100ML N019685 007 Oct 17, 1988 Jan CRLD

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP + ICU MEDICAL INC 20MG/100ML;5GM/100ML;179MG/100ML;6 00MG/100ML;310MG/100ML N019685 002 Oct 17, 1988 Jan CRLD

+ @ 20MG/100ML;5GM/100ML;328MG/100ML; N019685 008 Oct 17, 1988 Jan DISC

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
		600MG/100ML; 310MG/100ML							
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685	003	Oct 17, 1988			Jan	CRLD
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685	004	Oct 17, 1988			Jan	DISC
		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER							
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	001	Oct 17, 1988			Jan	CRLD

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	+	ANI PHARMS INC	4MG	N020838	001	Jun 04, 1998	Jan	CAHN
AB	+		8MG	N020838	002	Jun 04, 1998	Jan	CAHN
AB	+		16MG	N020838	003	Jun 04, 1998	Jan	CAHN
AB	+		32MG	N020838	004	Jun 04, 1998	Jan	CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

>A>	AB	+	ANI PHARMS INC	16MG; 12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN
>A>	AB	+		32MG; 12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN
>A>	AB	+		32MG; 25MG	N021093	003	May 16, 2008	Feb	CAHN
>D>	AB	+	ASTRAZENECA	16MG; 12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN
>D>	AB	+		32MG; 12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN
>D>	AB	+		32MG; 25MG	N021093	003	May 16, 2008	Feb	CAHN

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ YAOPHARMA CO LTD

		12.5MG	A074363	001	Nov 09, 1995	Jan	CAHN
		12.5MG	A074519	001	Feb 13, 1996	Jan	CAHN
		25MG	A074363	002	Nov 09, 1995	Jan	CAHN
		25MG	A074519	002	Feb 13, 1996	Jan	CAHN
		50MG	A074363	003	Nov 09, 1995	Jan	CAHN
		50MG	A074519	003	Feb 13, 1996	Jan	CAHN
		100MG	A074363	004	Nov 09, 1995	Jan	CAHN
		100MG	A074519	004	Feb 13, 1996	Jan	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

		@ G AND W LABS INC	25MG; 15MG	A074827	001	Dec 29, 1997	Jan	DISC
		@	25MG; 25MG	A074827	002	Dec 29, 1997	Jan	DISC
		@	50MG; 15MG	A074827	004	Dec 29, 1997	Jan	DISC
		@	50MG; 25MG	A074827	003	Dec 29, 1997	Jan	DISC
		MYLAN	25MG; 15MG	A074896	001	Dec 29, 1997	Jan	CTEC
		!	25MG; 25MG	A074896	002	Dec 29, 1997	Jan	CTEC
		!	50MG; 15MG	A074896	004	Dec 29, 1997	Jan	CTEC
		!	50MG; 25MG	A074896	003	Dec 29, 1997	Jan	CTEC

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

+		ALLERGAN SALES LLC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CAHN
+			EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CAHN
+			EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan	CAHN
+		!	EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

		@ FOSUN PHARMA	350MG	A081025	001	Apr 13, 1989	Jan	CAHN
--	--	----------------	-------	---------	-----	--------------	-----	------

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
 CEFEPIME HYDROCHLORIDE
 @ FOSUN PHARMA
 @
 @

EQ 500MG BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 2GM BASE/VIAL

A 090291 001 Dec 21, 2010 Jan CAHN
 A 090291 002 Dec 21, 2010 Jan CAHN
 A 090291 003 Dec 21, 2010 Jan CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
 CEFOTAXIME SODIUM

>D> AP
 >A>
 >D> AP
 >A>
 >D> AP
 >A>

LUPIN
 @
 @
 @
 @

EQ 500MG BASE/VIAL
 EQ 500MG BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 2GM BASE/VIAL
 EQ 2GM BASE/VIAL

A 065124 001 Sep 24, 2003 Feb DISC
 A 065124 001 Sep 24, 2003 Feb DISC
 A 065124 002 Sep 24, 2003 Feb DISC
 A 065124 002 Sep 24, 2003 Feb DISC
 A 065124 003 Sep 24, 2003 Feb DISC
 A 065124 003 Sep 24, 2003 Feb DISC

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)
 TEFLARO

+ ALLERGAN SALES LLC
 +!

400MG/VIAL
 600MG/VIAL

N 200327 001 Oct 29, 2010 Jan CAHN
 N 200327 002 Oct 29, 2010 Jan CAHN

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL
 CEDAX

@ SI PHARMS
 FOR SUSPENSION; ORAL
 CEDAX

+ @ SI PHARMS
 + @

EQ 400MG BASE
 EQ 90MG BASE/5ML
 EQ 180MG BASE/5ML

N 050685 002 Dec 20, 1995 Jan CAHN
 N 050686 001 Dec 20, 1995 Jan CAHN
 N 050686 002 Dec 20, 1995 Jan CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION
 CEFTRIAZONE

>D> AP
 >A>

LUPIN
 @

EQ 10GM BASE/VIAL
 EQ 10GM BASE/VIAL

A 065263 001 Sep 12, 2006 Feb DISC
 A 065263 001 Sep 12, 2006 Feb DISC

CEFUROXIME AXETIL

TABLET; ORAL
 CEFUROXIME AXETIL

@ SANDOZ INC
 @

EQ 250MG BASE
 EQ 500MG BASE

A 065126 001 Oct 28, 2003 Jan CAHN
 A 065126 002 Oct 28, 2003 Jan CAHN

CELECOXIB

CAPSULE; ORAL
 CELECOXIB

AB CSPC OUYI PHARM CO
 AB
 AB

50MG
 100MG
 200MG

A 210071 001 Jan 23, 2018 Jan NEWA
 A 210071 002 Jan 23, 2018 Jan NEWA
 A 210071 003 Jan 23, 2018 Jan NEWA

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
 SONAZINE

@ FOSUN PHARMA
 @

30MG/ML
 100MG/ML

A 080983 004 Jan CAHN
 A 080983 005 Jan CAHN

SYRUP; ORAL
 SONAZINE

@ FOSUN PHARMA

10MG/5ML

A 083040 001 Jan CAHN

CICLOPIROX

SOLUTION; TOPICAL
 CICLOPIROX

AT INGENUS PHARMS LLC

8%

A 078124 001 Sep 18, 2007 Jan CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@	CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994	Jan CMS1
@		300MG	A074329	003	May 17, 1994	Jan CMS1
@		400MG	A074329	004	May 17, 1994	Jan CMS1
@	YAOPHARMA CO LTD	200MG	A074100	001	Jan 31, 1995	Jan CAHN
@		300MG	A074100	002	Jan 31, 1995	Jan CAHN
@		400MG	A074100	003	Jan 31, 1995	Jan CAHN
@		800MG	A074100	004	Jan 31, 1995	Jan CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

>A>							
>A>	AB	AUROBINDO PHARMA LTD	EQ 30MG BASE	A206125	001	Mar 08, 2018	Feb NEWA
>A>	AB		EQ 60MG BASE	A206125	002	Mar 08, 2018	Feb NEWA
>A>	AB		EQ 90MG BASE	A206125	003	Mar 08, 2018	Feb NEWA
>A>	AB	CIPLA LTD	EQ 30MG BASE	A208915	001	Mar 08, 2018	Feb NEWA
>A>	AB		EQ 60MG BASE	A208915	002	Mar 08, 2018	Feb NEWA
>A>	AB		EQ 90MG BASE	A208915	003	Mar 08, 2018	Feb NEWA
		SENSIPAR					
>D>	+	AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004	Feb CFTG
>A>	AB		EQ 30MG BASE	N021688	001	Mar 08, 2004	Feb CFTG
>D>	+		EQ 60MG BASE	N021688	002	Mar 08, 2004	Feb CFTG
>A>	AB		EQ 60MG BASE	N021688	002	Mar 08, 2004	Feb CFTG
>D>	+		EQ 90MG BASE	N021688	003	Mar 08, 2004	Feb CFTG
>A>	AB		EQ 90MG BASE	N021688	003	Mar 08, 2004	Feb CFTG

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		INFORLIFE	200MG/100ML	A078252	001	Mar 18, 2008	Jan CAHN
AP			400MG/200ML	A078252	002	Mar 18, 2008	Jan CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	FOSUN PHARMA	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan CAHN
@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan CAHN
@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@	FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007	Jan CAHN
---	--------------	-------------------------	---------	-----	--------------	----------

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+	ALLERGAN SALES LLC	EQ 10MG BASE	N020822	001	Apr 27, 2000	Jan CAHN
AB	+		EQ 20MG BASE	N020822	002	Jul 17, 1998	Jan CAHN
AB	+		EQ 40MG BASE	N020822	003	Jul 17, 1998	Jan CAHN
		@	EQ 60MG BASE	N020822	004	Jul 17, 1998	Jan CAHN
		CITALOPRAM HYDROBROMIDE					
@		FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004	Jan CAHN
@			EQ 10MG BASE	A077040	001	Aug 17, 2005	Jan CAHN
@			EQ 20MG BASE	A077035	002	Oct 28, 2004	Jan CAHN
@			EQ 20MG BASE	A077040	002	Aug 17, 2005	Jan CAHN
@			EQ 40MG BASE	A077035	003	Oct 28, 2004	Jan CAHN
@			EQ 40MG BASE	A077040	003	Aug 17, 2005	Jan CAHN

CLINDAMYCIN PHOSPHATE

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		GLASSHOUSE PHARMS	EQ 1% BASE	A209846	001	Feb 08, 2018	Jan NEWA
----	--	-------------------	------------	---------	-----	--------------	----------

CLOBETASOL PROPIONATE

	CREAM;TOPICAL						
	CLOBETASOL PROPIONATE						
AB1	LUPIN LTD	0.05%	A210208	001	Jan 30, 2018	Jan	NEWA
	IMPOYZ						
	+! ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017	Jan	CAHN

CLONIDINE HYDROCHLORIDE

	TABLET;ORAL						
	CLONIDINE HYDROCHLORIDE						
	@ AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988	Jan	CMS1
	@	0.3MG	A070886	003	Aug 31, 1988	Jan	CMS1
	TABLET, EXTENDED RELEASE;ORAL						
	CLONIDINE HYDROCHLORIDE						
AB1	JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018	Jan	NEWA

CLOZAPINE

	TABLET;ORAL						
	CLOZAPINE						
>D>	AB	ZYDUS PHARMS USA INC	25MG	A209480	001	Dec 06, 2017	Feb DISC
>A>	@		25MG	A209480	001	Dec 06, 2017	Feb DISC
>D>	AB		50MG	A209480	002	Dec 06, 2017	Feb DISC
>A>	@		50MG	A209480	002	Dec 06, 2017	Feb DISC
>D>	AB		100MG	A209480	003	Dec 06, 2017	Feb DISC
>A>	@		100MG	A209480	003	Dec 06, 2017	Feb DISC
>D>	AB		200MG	A209480	004	Dec 06, 2017	Feb DISC
>A>	@		200MG	A209480	004	Dec 06, 2017	Feb DISC

CROMOLYN SODIUM

	SOLUTION/DROPS;OPHTHALMIC						
	CROMOLYN SODIUM						
AT	SANDOZ INC	4%	A075282	001	Jun 16, 1999	Jan	CAHN

CROTAMITON

	CREAM;TOPICAL						
	EURAX						
>D>	+!	RANBAXY	10%	N006927	001		Feb CAHN
>A>	+!	SUN PHARM INDS INC	10%	N006927	001		Feb CAHN
	LOTION;TOPICAL						
	EURAX						
>D>	AT	+! RANBAXY	10%	N009112	003		Feb CAHN
>A>	AT	+! SUN PHARM INDS INC	10%	N009112	003		Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	CYCLOGYL						
>A>	AT	! ALCON LABS INC	0.5%	A084109	001		Feb CAHN
>A>	AT	!	1%	A084110	001		Feb CAHN
>A>		!	2%	A084108	001		Feb CAHN
>D>	AT	! NOVARTIS PHARMS CORP	0.5%	A084109	001		Feb CAHN
>D>	AT	!	1%	A084110	001		Feb CAHN
>D>		!	2%	A084108	001		Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	CYCLOMYDRIL						
>A>	!	ALCON LABS INC	0.2%;1%	A084300	001		Feb CAHN
>D>	!	NOVARTIS PHARMS CORP	0.2%;1%	A084300	001		Feb CAHN

CYPROHEPTADINE HYDROCHLORIDE

	TABLET;ORAL						
	CYPROHEPTADINE HYDROCHLORIDE						
	@ FOSUN PHARMA	4MG	A086808	001		Jan	CAHN
AA	MOUNTAIN	4MG	A040537	001	Sep 30, 2003	Jan	CAHN

CYTARABINEINJECTABLE; INJECTION
CYTARABINE

AP	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Jan	CAHN
----	----------------	---------	---------	-----	--------------	-----	------

DAPTOMYCINPOWDER; INTRAVENOUS
DAPTOMYCIN

>D>	AP	TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016	Feb	CAHN
>A>	AP	TEVA PHARMS USA	500MG/VIAL	A091039	001	Mar 25, 2016	Feb	CAHN

DESFLURANELIQUID; INHALATION
DESFLURANE

>A>	AN	SHANGHAI HENGRUI	100%	A208234	001	Feb 26, 2018	Feb	NEWA
>D>		+! BAXTER HLTHCARE	99.9%	N020118	001	Sep 18, 1992	Feb	CFTG
>A>	AN	+!	100%	N020118	001	Sep 18, 1992	Feb	CFTG

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

>D>	AB	COREPHARMA	10MG	A205153	001	Oct 28, 2016	Feb	CAHN
>D>	AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
>D>	AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
>D>	AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
>D>	AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
>D>	AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN
>A>	AB	MOUNTAIN	10MG	A205153	001	Oct 28, 2016	Feb	CAHN
>A>	AB		25MG	A205153	002	Oct 28, 2016	Feb	CAHN
>A>	AB		50MG	A205153	003	Oct 28, 2016	Feb	CAHN
>A>	AB		75MG	A205153	004	Oct 28, 2016	Feb	CAHN
>A>	AB		100MG	A205153	005	Oct 28, 2016	Feb	CAHN
>A>	AB		150MG	A205153	006	Oct 28, 2016	Feb	CAHN

DEXAMETHASONEELIXIR; ORAL
HEXADROL

>A>	@	ASPEN GLOBAL INC	0.5MG/5ML	N012674	001		Feb	CAHN
>D>	@	ORGANON USA INC	0.5MG/5ML	N012674	001		Feb	CAHN
>A>		SUSPENSION; INTRAOCULAR						
>A>		DEXYCU KIT						
>A>		+! ICON BIOSCIENCE	9%	N208912	001	Feb 09, 2018	Feb	NEWA

TABLET; ORAL
DEXAMETHASONE

BP	FERA PHARMS LLC	0.5MG	A088148	001	Apr 28, 1983	Jan	CAHN
BP		0.75MG	A088160	001	Apr 28, 1983	Jan	CAHN
BP		4MG	A088238	001	Apr 28, 1983	Jan	CAHN
BP		6MG	A088481	001	Nov 28, 1983	Jan	CAHN

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTION
HEXADROL

>A>	+ @	ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML	N014694	002		Feb	CAHN
>A>	+ @		EQ 10MG PHOSPHATE/ML	N014694	003		Feb	CAHN
>A>	@		EQ 20MG PHOSPHATE/ML	N014694	004		Feb	CAHN
>D>	+ @	ORGANON USA INC	EQ 4MG PHOSPHATE/ML	N014694	002		Feb	CAHN
>D>	+ @		EQ 10MG PHOSPHATE/ML	N014694	003		Feb	CAHN
>D>	@		EQ 20MG PHOSPHATE/ML	N014694	004		Feb	CAHN

DEXMEDETOMIDINE HYDROCHLORIDEINJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

>A>	AP	ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798	001	Feb 27, 2018	Feb	NEWA
-----	----	----------------------	--	---------	-----	--------------	-----	------

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH W/ DEXTROMETHORPHAN

@ G AND W LABS INC 15MG/5ML;6.25MG/5ML A088762 001 Oct 31, 1984 Jan DISC

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

>D> AP +! HOSPIRA 50MG/ML N019222 001 Jul 13, 1984 Feb CAHN

>A> AP +! ICU MEDICAL INC 50MG/ML N019222 001 Jul 13, 1984 Feb CAHN

DEXTROSE 70% IN PLASTIC CONTAINER

>A> AP +! B BRAUN 70GM/100ML N019626 005 Feb 18, 2015 Feb NEWA

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP + ICU MEDICAL INC 5GM/100ML;450MG/100ML N017607 001 Jan CRLD

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

AB +! ALLERGAN SALES LLC 10MG N007409 003 Oct 15, 1984 Jan CAHN

INJECTABLE;INJECTION

BENTYL

AP +! ALLERGAN SALES LLC 10MG/ML N008370 001 Oct 15, 1984 Jan CAHN

BENTYL PRESERVATIVE FREE

AP +! ALLERGAN SALES LLC 10MG/ML N008370 002 Oct 15, 1984 Jan CAHN

TABLET;ORAL

BENTYL

AB +! ALLERGAN SALES LLC 20MG N007409 001 Oct 15, 1984 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

@ FOSUN PHARMA 25MG A080832 001 Jan CAHN

@ 25MG A080845 002 Jan CAHN

@ 50MG A080832 002 Jan CAHN

@ 50MG A080845 001 Jan CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP ANNEAL PHARMS CO 20MG/ML (20MG/ML) A209640 001 Jan 19, 2018 Jan NEWA

AP 80MG/4ML (20MG/ML) A209640 002 Jan 19, 2018 Jan NEWA

AP 160MG/8ML (20MG/ML) A209640 003 Jan 19, 2018 Jan NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ ZAMBON SPA EQ 2% BASE;EQ 0.5% BASE A091180 001 Dec 04, 2013 Jan DISC

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

AB HERITAGE PHARMA EQ 1MG BASE A205210 001 Feb 13, 2018 Jan NEWA

AB EQ 2MG BASE A205210 002 Feb 13, 2018 Jan NEWA

AB EQ 4MG BASE A205210 003 Feb 13, 2018 Jan NEWA

AB EQ 8MG BASE A205210 004 Feb 13, 2018 Jan NEWA

AB IDT AUSTRALIA LTD EQ 1MG BASE A075432 001 Oct 18, 2000 Jan CMFD

AB EQ 2MG BASE A075432 002 Oct 18, 2000 Jan CMFD

AB EQ 4MG BASE A075432 003 Oct 18, 2000 Jan CMFD

AB EQ 8MG BASE A075432 004 Oct 18, 2000 Jan CMFD

@ YAOPHARMA CO LTD EQ 1MG BASE A075646 001 Oct 18, 2000 Jan CAHN

@ EQ 2MG BASE A075646 002 Oct 18, 2000 Jan CAHN

@ EQ 4MG BASE A075646 003 Oct 18, 2000 Jan CAHN

@ EQ 8MG BASE A075646 004 Oct 18, 2000 Jan CAHN

DOXEPIH HYDROCHLORIDE

TABLET;ORAL

DOXEPIH HYDROCHLORIDE

@	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jan DISC
@		EQ 6MG BASE	A201951	002	Jul 26, 2013	Jan DISC
SILENOR						
+	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jan CTEC
+	!	EQ 6MG BASE	N022036	002	Mar 17, 2010	Jan CTEC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

LO-ZUMANDIMINE

>A>	AB	AUROBINDO PHARMA LTD	3MG;0.02MG	A209632	001	Feb 27, 2018	Feb NEWA
-----	----	----------------------	------------	---------	-----	--------------	----------

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

>A>	AB	STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018	Feb NEWA
-----	----	----------------	-------	---------	-----	--------------	----------

>A> EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

>A> TABLET;ORAL

>A> SYMFI LO

>A>	+	MYLAN PHARMS INC	400MG;300MG;300MG	N208255	001	Feb 05, 2018	Feb NEWA
-----	---	------------------	-------------------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	200MG;300MG	A090513	001	Jan 26, 2018	Jan NEWA
----	--	----------------------	-------------	---------	-----	--------------	----------

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

>A>	AP	SAGENT PHARMS	2MG/ML	A204693	001	Mar 07, 2018	Feb NEWA
>A>	AP		75MG/100ML	A204693	002	Mar 07, 2018	Feb NEWA

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

+	MERCK SHARP DOHME	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017	Jan CMS1
+	!	15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017	Jan CMS1

ERYTHROMYCIN

TABLET;ORAL

ERYTHROMYCIN

>A>	AB	AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Feb NEWA
>A>	AB		500MG	A209720	002	Mar 09, 2018	Feb NEWA
>D>		ARBOR PHARMS LLC	250MG	A061621	001		Feb CTEC
>A>	AB		250MG	A061621	001		Feb CTEC
>D>	!		500MG	A061621	002		Feb CTEC
>A>	AB	!	500MG	A061621	002		Feb CTEC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

LEXAPRO

AA	+	ALLERGAN SALES LLC	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan CAHN
----	---	--------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

LEXAPRO

AB	+	ALLERGAN SALES LLC	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan CAHN
AB	+		EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan CAHN
AB	+	!	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan CAHN

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

>A>	AB	ALVOGEN PINE BROOK	0.01%	A209767	001	Mar 05, 2018	Feb NEWA
	AB	PERRIGO UK FINCO	0.01%	A210194	001	Jan 22, 2018	Jan NEWA

ESTRADIOL VALERATE

INJECTABLE; INJECTION
ESTRADIOL VALERATE

@	FOSUN PHARMA	10MG/ML	A 040628	001	Oct 04, 2007	Jan	CAHN
@		20MG/ML	A 040628	002	Oct 04, 2007	Jan	CAHN
@		40MG/ML	A 040628	003	Oct 04, 2007	Jan	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

>A>	AB	ACCORD HLTHCARE	1MG;0.5MG	A 210233	001	Feb 28, 2018	Feb	NEWA
-----	----	-----------------	-----------	----------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL
BALCOLTRA

>A>		AVION PHARMS	0.02MG;0.1MG	N 208612	001	Jan 09, 2018	Feb	CAHN
>D>		NEUVOSYN LABS LLC	0.02MG;0.1MG	N 208612	001	Jan 09, 2018	Feb	CAHN
			0.02MG;0.1MG	N 208612	001	Jan 09, 2018	Jan	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
MODICON 28

>D>	AB	+!	JANSSEN PHARMS	0.035MG;0.5MG	N 017735	001		Feb	DISC
>A>		+ @		0.035MG;0.5MG	N 017735	001		Feb	DISC
			WERA						
>D>	AB		NOVAST LABS LTD	0.035MG;0.5MG	A 091204	001	Mar 27, 2012	Feb	CHRS
>A>	AB	!		0.035MG;0.5MG	A 091204	001	Mar 27, 2012	Feb	CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET, CHEWABLE, TABLET; ORAL
LO MINASTRIN FE

+ @	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N 204654	001	Jul 24, 2013	Jan	DISC
-----	------	-------------------------------	----------	-----	--------------	-----	------

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE

>A>		@	PLD ACQUISITIONS	20MG	A 075302	001	Apr 16, 2001	Feb	CAHN
>A>		@		40MG	A 075302	002	Apr 16, 2001	Feb	CAHN
>D>		@	SANDOZ	20MG	A 075302	001	Apr 16, 2001	Feb	CAHN
>D>		@		40MG	A 075302	002	Apr 16, 2001	Feb	CAHN

FENOFIBRATE

TABLET; ORAL
FENOFIBRATE

AB			AMNEAL PHARMS LLC	48MG	A 209951	001	Feb 09, 2018	Jan	NEWA
AB				145MG	A 209951	002	Feb 09, 2018	Jan	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC-37

+	JANSSEN PHARMS	37.5MCG/HR	N 019813	006	Jan 24, 2018	Jan	NEWA
---	----------------	------------	----------	-----	--------------	-----	------

FLUCONAZOLE

INJECTABLE; INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	!	INFORLIFE	200MG/100ML (2MG/ML)	A 079104	001	Jul 30, 2009	Jan	CAHN
AP	!		400MG/200ML (2MG/ML)	A 079104	002	Jul 30, 2009	Jan	CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

@	G AND W LABS	0.025%	A 089525	001	Jul 26, 1988	Jan	DISC
---	--------------	--------	----------	-----	--------------	-----	------

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE

@	G AND W LABS INC	0.01%	A 207441	001	Sep 28, 2016	Jan	DISC
---	------------------	-------	----------	-----	--------------	-----	------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS
FLUORESCITE

>A>	AP	+	ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb	CAHN
>D>	AP	+	NOVARTIS PHARMS CORP	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb	CAHN

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL
FLUOXETINE HYDROCHLORIDE
@ FOSUN PHARMA

EQ 10MG BASE

A076024 001 Jan 29, 2002 Jan CAHN

FLUTAMIDE

CAPSULE; ORAL
FLUTAMIDE

@ YAOPHARMA CO LTD

125MG

A075818 001 Sep 18, 2001 Jan CAHN

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL
XHANCE

+! OPTINOSE US INC

0.093MG

N209022 001 Sep 18, 2017 Jan CMS1

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB EMCURE PHARMS LTD

10MG; 12.5MG

A079025 001 Sep 17, 2010 Jan CAHN

AB !

20MG; 12.5MG

A079025 002 Sep 17, 2010 Jan CAHN

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

@ YAOPHARMA CO LTD

600MG

A074615 001 Sep 29, 1995 Jan CAHN

GENTAMICIN SULFATE

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT G AND W LABS INC

EQ 0.1% BASE

A064054 001 Apr 29, 1994 Jan CMFD

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS
GLATOPIA

AP SANDOZ INC

40MG/ML

A206921 001 Feb 12, 2018 Jan NEWA

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

@ YAOPHARMA CO LTD

1.5MG

A075174 001 Jun 22, 1998 Jan CAHN

@

3MG

A075174 002 Jun 22, 1998 Jan CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

 >D> | AP | ! | TEVA PHARMS USA | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A077963 | 001 | Jan 03, 2008 | Feb | DISC |

>A> |

@ |

EQ 1MG BASE/ML (EQ 1MG BASE/ML) |

A077963 001 Jan 03, 2008 Feb DISC |

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZED

AB MOUNTAIN

125MG

A204371 001 Jan 09, 2014 Jan CAHN

AB

250MG

A204371 002 Jan 09, 2014 Jan CAHN

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

@ YAOPHARMA CO LTD

EQ 4MG BASE

A074517 001 Sep 30, 1998 Jan CAHN

@

EQ 8MG BASE

A074517 002 Sep 30, 1998 Jan CAHN

HALCINONIDECREAM; TOPICAL
HALOG

>D>	+	RANBAXY	0.1%	N017556	001		Feb	CAHN
>A>	+	SUN PHARM INDS INC	0.1%	N017556	001		Feb	CAHN

HALOBETASOL PROPIONATECREAM; TOPICAL
ULTRAVATE

>A>	AB	+	SUN PHARM INDS INC	0.05%	N019967	001	Dec 27, 1990	Feb	CAHN
>D>	AB	+	SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Feb	CAHN

OINTMENT; TOPICAL
ULTRAVATE

>D>	AB	+	RANBAXY	0.05%	N019968	001	Dec 17, 1990	Feb	CAHN
>A>	AB	+	SUN PHARM INDS INC	0.05%	N019968	001	Dec 17, 1990	Feb	CAHN

HALOPERIDOL LACTATEINJECTABLE; INJECTION
HALOPERIDOL

@	FOSUN PHARMA	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Jan	CAHN
---	--------------	----------------	---------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	AA		SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	Feb	CAHN
>A>	AA			25MG	A205236	002	May 26, 2017	Feb	CAHN
>A>	AA			50MG	A205236	003	May 26, 2017	Feb	CAHN
>A>	AA			100MG	A205236	004	May 26, 2017	Feb	CAHN
>D>	AA		TECH ORGANIZED	10MG	A205236	001	May 26, 2017	Feb	CAHN
>D>	AA			25MG	A205236	002	May 26, 2017	Feb	CAHN
>D>	AA			50MG	A205236	003	May 26, 2017	Feb	CAHN
>D>	AA			100MG	A205236	004	May 26, 2017	Feb	CAHN

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB			SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014	Jan	CAHN
AB				50MG	A203018	002	Jul 23, 2014	Jan	CAHN
		@	YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982	Jan	CAHN
		@		50MG	A084912	001		Jan	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	15MG; 250MG	A070182	001	Jan 15, 1986	Jan	CAHN
@		25MG; 250MG	A070183	001	Jan 15, 1986	Jan	CAHN
@		30MG; 500MG	A070543	001	Jan 15, 1986	Jan	CAHN
@		50MG; 500MG	A070544	001	Jan 15, 1986	Jan	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	25MG; 40MG	A071060	001	Aug 26, 1987	Jan	CAHN
@		25MG; 80MG	A071061	001	Aug 26, 1987	Jan	CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	25MG; 25MG	A086881	001		Jan	CAHN
---	------------------	------------	---------	-----	--	-----	------

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+	@	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan	DISC
+	@		30MG	N207975	002	Jan 17, 2017	Jan	DISC
+	@		45MG	N207975	003	Jan 17, 2017	Jan	DISC
+	@		60MG	N207975	004	Jan 17, 2017	Jan	DISC
+	@		90MG	N207975	005	Jan 17, 2017	Jan	DISC

HYDROCORTISONE VALERATE

OINTMENT;TOPICAL
WESTCORT

>D>	+ @ RANBAXY	0.2%	N018726	001	Aug 08, 1983	Feb CAHN
>A>	+ @ SUN PHARM INDS INC	0.2%	N018726	001	Aug 08, 1983	Feb CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET;ORAL
HYDROMORPHONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	2MG	A210506	001	Jan 17, 2018	Jan NEWA
AB		4MG	A210506	002	Jan 17, 2018	Jan NEWA
AB		8MG	A210506	003	Jan 17, 2018	Jan NEWA

HYDROXYPROGESTERONE CAPROATE

SOLUTION;SUBCUTANEOUS
MAKENA (AUTOINJECTOR)

>A>	+! AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Feb NEWA
-----	--------------------	------------------------	---------	-----	--------------	----------

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL
ATARAX

>D>	@ PFIZER	10MG	N010392	001		Feb CRLD
>A>	+ @	10MG	N010392	001		Feb CRLD
>D>	@	25MG	N010392	004		Feb CRLD
>A>	+ @	25MG	N010392	004		Feb CRLD
>D>	@	50MG	N010392	006		Feb CRLD
>A>	+ @	50MG	N010392	006		Feb CRLD
>D>	@	100MG	N010392	005		Feb CRLD
>A>	+ @	100MG	N010392	005		Feb CRLD

IBRUTINIB

TABLET;ORAL
IMBRUVICA

>A>	+ PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018	Feb NEWA
>A>	+	280MG	N210563	002	Feb 16, 2018	Feb NEWA
>A>	+	420MG	N210563	003	Feb 16, 2018	Feb NEWA
>A>	+!	560MG	N210563	004	Feb 16, 2018	Feb NEWA

IBUPROFEN

SUSPENSION;ORAL
IBUPROFEN

>A>	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	Feb NEWA
-----	----------------------	-----------	---------	-----	--------------	----------

IBUTILIDE FUMARATE

INJECTABLE;INJECTION
IBUTILIDE FUMARATE

@ MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010	Jan DISC
-----------------------	----------	---------	-----	--------------	----------

IMIQUIMOD

CREAM;TOPICAL
IMIQUIMOD

@ G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Jan DISC
--------------------	----	---------	-----	--------------	----------

INDAPAMIDE

TABLET;ORAL
INDAPAMIDE

@ YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996	Jan CAHN
@	2.5MG	A074594	002	May 23, 1996	Jan CAHN

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL
ATROVENT

+ @ BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995	Jan DISC
+ @	0.042MG/SPRAY	N020394	001	Oct 20, 1995	Jan DISC
AB ! WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Jan CHRS
AB !	0.042MG/SPRAY	A076598	001	Nov 05, 2003	Jan CHRS

>A>	<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR</u>								
>A>	TABLET, TABLET;ORAL								
>A>	SYMDEKO (COPACKAGED)								
>A>	+	VERTEX PHARMS INC	150MG,N/A;150MG, 100MG		N210491	001	Feb 12, 2018	Feb	NEWA
	<u>KETOROLAC TROMETHAMINE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	KETOROLAC TROMETHAMINE								
AT		SANDOZ INC	0.4%		A078721	001	Nov 05, 2009	Jan	CAHN
>A>	<u>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE</u>								
>A>	TABLET;ORAL								
>A>	CIMDUO								
>A>	+	MYLAN LABS LTD	300MG;300MG		N022141	001	Feb 28, 2018	Feb	NEWA
	<u>LEFLUNOMIDE</u>								
	TABLET;ORAL								
	LEFLUNOMIDE								
	@	FOSUN PHARMA	10MG		A077087	001	Sep 13, 2005	Jan	CAHN
	@		20MG		A077087	002	Sep 13, 2005	Jan	CAHN
	<u>LEUPROLIDE ACETATE</u>								
	INJECTABLE;INJECTION								
	LUPRON								
>D>	@	ABBVIE ENDOCRINE INC	1MG/0.2ML		N019010	001	Apr 09, 1985	Feb	CRLD
>A>	+	@	1MG/0.2ML		N019010	001	Apr 09, 1985	Feb	CRLD
	<u>LEVETIRACETAM</u>								
	TABLET;ORAL								
	LEVETIRACETAM								
	@	FOSUN PHARMA	250MG		A077324	001	Jan 15, 2009	Jan	CAHN
	@		500MG		A077324	002	Jan 15, 2009	Jan	CAHN
	@		750MG		A077324	003	Jan 15, 2009	Jan	CAHN
	@		1GM		A077324	004	Jan 15, 2009	Jan	CAHN
	<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>								
	TABLET;ORAL								
	LEVOCETIRIZINE DIHYDROCHLORIDE								
	@	FOSUN PHARMA	5MG		A090486	001	Mar 26, 2013	Jan	CAHN
	<u>LEVOFLOXACIN</u>								
	INJECTABLE;INJECTION								
>D>	LEVAQUIN								
>D>	AP	+	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Feb	DISC
>A>		+	@	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Feb	DISC
>D>	AP	+	!	EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Feb	DISC
>A>		+	@	EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Feb	DISC
	LEVOFLOXACIN								
>D>	AP		ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb	DISC
>A>		@		EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb	DISC
>D>	AP		!	EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb	DISC
>A>		@		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb	DISC
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER								
AP	!	!	INFORLIFE	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jan	CAHN
AP	!	!		EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jan	CAHN
AP	!	!		EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jan	CAHN
	TABLET;ORAL								
>D>	LEVAQUIN								
>D>	AB	+	JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996	Feb	DISC
>A>		+	@	250MG	N020634	001	Dec 20, 1996	Feb	DISC
>D>	AB	+	!	500MG	N020634	002	Dec 20, 1996	Feb	DISC
>A>		+	@	500MG	N020634	002	Dec 20, 1996	Feb	DISC
>D>	AB	+	!	750MG	N020634	003	Sep 08, 2000	Feb	DISC
>A>		+	@	750MG	N020634	003	Sep 08, 2000	Feb	DISC
	LEVOFLOXACIN								
>D>	AB		AUROBINDO PHARMA LTD	750MG	A201043	003	Jun 20, 2011	Feb	CHRS
>A>	AB	!	!	750MG	A201043	003	Jun 20, 2011	Feb	CHRS

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
FETZIMA

	+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CAHN
	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
	+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

AP		PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jan CAHN
AP			500MCG/VIAL	A206163	002	Jun 29, 2016	Jan CAHN

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

AT		TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Jan NEWA	
>A>								
>A>		!	SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018	Feb NEWA

LINACLOTIDE

CAPSULE;ORAL
LINZESS

	+	ALLERGAN SALES LLC	72MCG	N202811	003	Jan 25, 2017	Jan CAHN
	+		145MCG	N202811	001	Aug 30, 2012	Jan CAHN
	+	!	290MCG	N202811	002	Aug 30, 2012	Jan CAHN

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE
@ YAOPHARMA CO LTD

			2MG	A072993	001	Aug 28, 1992	Jan CAHN
--	--	--	-----	---------	-----	--------------	----------

LORAZEPAM

TABLET;ORAL
LORAZEPAM

		@ MYLAN	0.5MG	A071591	002	Oct 13, 1987	Jan CMS1
		@	1MG	A071591	003	Oct 13, 1987	Jan CMS1

LUTETIUM DOTATATE LU-177

SOLUTION;IV (INFUSION)
LUTATHERA

	+	!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jan NEWA
--	---	---	-------------	----------	---------	-----	--------------	----------

MACIMORELIN ACETATE

FOR SOLUTION;ORAL
MACRILEN

	+	!	STRONGBRIDGE IRELAND	EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Jan CAHN
--	---	---	----------------------	--------------------	---------	-----	--------------	----------

MEBENDAZOLE

TABLET, CHEWABLE;ORAL
VERMOX

>D>								
>D>		+	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Feb DISC
>A>		+	@	500MG	N208398	001	Oct 19, 2016	Feb DISC

MECLOFENAMATE SODIUM

CAPSULE;ORAL
MECLOFENAMATE SODIUM

		@ FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan CAHN
		@	EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan CAHN

MEFENAMIC ACID

CAPSULE;ORAL
MEFENAMIC ACID

>A>	AB		MICRO LABS	250MG	A090562	001	Nov 19, 2010	Feb CAHN
>D>	AB		VIVA HLTHCARE	250MG	A090562	001	Nov 19, 2010	Feb CAHN

MEMANTINE HYDROCHLORIDE

	SOLUTION; ORAL							
	MEMANTINE HYDROCHLORIDE							
AA	APOTEX INC	2MG/ML	A209955	001	Feb 09, 2018	Jan	NEWA	
	NAMENDA							
AA	+! ALLERGAN SALES LLC	2MG/ML	N021627	001	Apr 18, 2005	Jan	CAHN	
	TABLET; ORAL							
	NAMENDA							
AB	+ ALLERGAN SALES LLC	5MG	N021487	001	Oct 16, 2003	Jan	CAHN	
AB	+!	10MG	N021487	002	Oct 16, 2003	Jan	CAHN	

MEROPENEM; VABORBACTAM

	POWDER; IV (INFUSION)							
	VABOMERE							
	+! REMPEX PHARMS	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Jan	CAHN	

MESALAMINE

	ENEMA; RECTAL							
	MESALAMINE							
	@ G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Jan	DISC	
	SUPPOSITORY; RECTAL							
	CANASA							
	@ ALLERGAN SALES LLC	500MG	N021252	001	Jan 05, 2001	Jan	CAHN	
AB	+!	1GM	N021252	002	Nov 05, 2004	Jan	CAHN	

MESNA

	INJECTABLE; INTRAVENOUS							
	MESNA							
	@ MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Jan	DISC	

>D>	<u>METARAMINOL BITARTRATE</u>							
>D>	INJECTABLE; INJECTION							
>D>	METARAMINOL BITARTRATE							
>D>	! FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001		Feb	DISC	
>A>	@	EQ 10MG BASE/ML	A080722	001		Feb	DISC	

METAXALONE

	TABLET; ORAL							
	METAXALONE							
	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Jan	CAHN	
	@ PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015	Jan	CAHN	

METHOCARBAMOL

	TABLET; ORAL							
	METHOCARBAMOL							
>A>	AA ALLIED PHARMA INC	500MG	A203550	001	Feb 08, 2017	Feb	CAHN	
>A>	AA	750MG	A203550	002	Feb 08, 2017	Feb	CAHN	
>D>	AA ATLAS PHARMS LLC	500MG	A203550	001	Feb 08, 2017	Feb	CAHN	
>D>	AA	750MG	A203550	002	Feb 08, 2017	Feb	CAHN	
	@ FOSUN PHARMA	500MG	A084616	001		Jan	CAHN	
	@	750MG	A084615	001		Jan	CAHN	

METHYLCLOTHIAZIDE

	TABLET; ORAL							
	METHYLCLOTHIAZIDE							
	@ YAOPHARMA CO LTD	2.5MG	A089835	001	Aug 18, 1988	Jan	CAHN	
	@	5MG	A089837	001	Aug 18, 1988	Jan	CAHN	

METHYLDOPA

	TABLET; ORAL							
	METHYLDOPA							
	@ YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988	Jan	CAHN	
	@	250MG	N018934	001	Jun 29, 1984	Jan	CAHN	
	@	500MG	N018934	002	Jun 29, 1984	Jan	CAHN	

METHYLPHENIDATE HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE;ORAL							
		METHYLPHENIDATE HYDROCHLORIDE							
>A>	AB1	MAYNE PHARMA	10MG	A200886	001	Feb 26, 2018	Feb	NEWA	
		TABLET;ORAL							
		METHYLPHENIDATE HYDROCHLORIDE							
>A>	AB	BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Feb	NEWA	
>A>	AB		10MG	A209753	002	Mar 02, 2018	Feb	NEWA	
>A>	AB		20MG	A209753	003	Mar 02, 2018	Feb	NEWA	
	AB	MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Jan	CAHN	
	AB		10MG	A091159	002	Mar 12, 2014	Jan	CAHN	
	AB		20MG	A091159	003	Mar 12, 2014	Jan	CAHN	
		TABLET, EXTENDED RELEASE;ORAL							
		METHYLPHENIDATE HYDROCHLORIDE							
	AB	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jan	NEWA	
	AB		27MG	A207515	002	Feb 01, 2018	Jan	NEWA	
	AB		36MG	A207515	003	Feb 01, 2018	Jan	NEWA	
	AB		54MG	A207515	004	Feb 01, 2018	Jan	NEWA	
	AB	MOUNTAIN	18MG	A208607	001	Jul 14, 2017	Jan	CAHN	
	AB		27MG	A208607	002	Jul 14, 2017	Jan	CAHN	
	AB		36MG	A208607	003	Jul 14, 2017	Jan	CAHN	
	AB		54MG	A208607	004	Jul 14, 2017	Jan	CAHN	
	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Jan	CHRS	

METOCLOPRAMIDE HYDROCHLORIDE

		TABLET;ORAL							
		METOCLOPRAMIDE HYDROCHLORIDE							
	@	YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995	Jan	CAHN	
	@		EQ 10MG BASE	A072215	001	Jan 30, 1990	Jan	CAHN	
	@		EQ 10MG BASE	A074478	002	Oct 05, 1995	Jan	CAHN	

METOPROLOL SUCCINATE

		CAPSULE, EXTENDED RELEASE;ORAL							
		METOPROLOL SUCCINATE							
	+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jan	NEWA	
	+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jan	NEWA	
	+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jan	NEWA	
	+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jan	NEWA	
		TABLET, EXTENDED RELEASE;ORAL							
		METOPROLOL SUCCINATE							
	AB	NOVAST LABS LTD	EQ 25MG TARTRATE	A204106	001	Feb 06, 2018	Jan	NEWA	
	AB		EQ 50MG TARTRATE	A204106	002	Feb 06, 2018	Jan	NEWA	
	AB		EQ 100MG TARTRATE	A204106	003	Feb 06, 2018	Jan	NEWA	
	AB		EQ 200MG TARTRATE	A204106	004	Feb 06, 2018	Jan	NEWA	

METOPROLOL TARTRATE

		TABLET;ORAL							
		METOPROLOL TARTRATE							
	@	RENATA	50MG	A074453	001	Apr 27, 1995	Jan	CAHN	
	@		100MG	A074453	002	Apr 27, 1995	Jan	CAHN	
	@	YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994	Jan	CAHN	
	@		100MG	A073289	001	Mar 25, 1994	Jan	CAHN	

METRONIDAZOLE

		TABLET;ORAL							
		METRONIDAZOLE							
	@	FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982	Jan	CAHN	
	@		250MG	N018740	001	Oct 22, 1982	Jan	CAHN	
	@		500MG	N018620	002	Jun 02, 1983	Jan	CAHN	
	@		500MG	N018740	002	Oct 22, 1982	Jan	CAHN	

MIDODRINE HYDROCHLORIDE

		TABLET;ORAL							
		MIDODRINE HYDROCHLORIDE							
>D>	BX	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Feb	CTEC	
>A>	AB		2.5MG	A077746	001	Sep 12, 2006	Feb	CTEC	
>D>	BX		5MG	A077746	002	Sep 12, 2006	Feb	CTEC	
>A>	AB		5MG	A077746	002	Sep 12, 2006	Feb	CTEC	
>D>	BX		10MG	A077746	003	Sep 12, 2006	Feb	CTEC	
>A>	AB		10MG	A077746	003	Sep 12, 2006	Feb	CTEC	

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
 MINOCIN
 +! REMPEX PHARMS EQ 100MG BASE/VIAL N050444 001 Jan CAHN
 TABLET, EXTENDED RELEASE; ORAL
 MINOCYCLINE HYDROCHLORIDE
 AB BARR LABS INC EQ 65MG BASE A065485 004 May 18, 2012 Jan CMFD
 AB EQ 115MG BASE A065485 005 May 18, 2012 Jan CMFD

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
 NALTREXONE HYDROCHLORIDE
 @ FOSUN PHARMA 50MG A075434 001 Mar 08, 2000 Jan CAHN

NAPROXEN

TABLET; ORAL
 NAPROXEN
 @ FOSUN PHARMA 250MG A074140 001 Dec 21, 1993 Jan CAHN
 @ 375MG A074140 002 Dec 21, 1993 Jan CAHN
 @ 500MG A074140 003 Dec 21, 1993 Jan CAHN
 TABLET, DELAYED RELEASE; ORAL
 NAPROXEN
 @ FOSUN PHARMA 375MG A075061 001 Feb 18, 1998 Jan CAHN
 @ 500MG A075061 002 Feb 18, 1998 Jan CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL
 >A> SUMATRIPTAN AND NAPROXEN SODIUM
 >A> AB AUROBINDO PHARMA LTD 500MG; EQ 85MG BASE A207457 001 Feb 15, 2018 Feb NEWA
 TREXIMET
 >D> +! PERNIX IRELAND LTD 500MG; EQ 85MG BASE N021926 001 Apr 15, 2008 Feb CFTG
 >A> AB +! 500MG; EQ 85MG BASE N021926 001 Apr 15, 2008 Feb CFTG

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL
 BYSTOLIC
 >D> + ALLERGAN SALES LLC EQ 2.5MG BASE N021742 002 Dec 17, 2007 Feb CFTG
 >A> AB + EQ 2.5MG BASE N021742 002 Dec 17, 2007 Feb CFTG
 + EQ 2.5MG BASE N021742 002 Dec 17, 2007 Jan CAHN
 >D> + EQ 5MG BASE N021742 003 Dec 17, 2007 Feb CFTG
 >A> AB + EQ 5MG BASE N021742 003 Dec 17, 2007 Feb CFTG
 + EQ 5MG BASE N021742 003 Dec 17, 2007 Jan CAHN
 >D> + EQ 10MG BASE N021742 004 Dec 17, 2007 Feb CFTG
 >A> AB + EQ 10MG BASE N021742 004 Dec 17, 2007 Feb CFTG
 + EQ 10MG BASE N021742 004 Dec 17, 2007 Jan CAHN
 >D> +! EQ 20MG BASE N021742 005 Oct 08, 2008 Feb CFTG
 >A> AB +! EQ 20MG BASE N021742 005 Oct 08, 2008 Feb CFTG
 +! EQ 20MG BASE N021742 005 Oct 08, 2008 Jan CAHN
 >A> NEBIVOLOL HYDROCHLORIDE
 >A> AB TORRENT PHARMS LTD EQ 2.5MG BASE A203966 001 Mar 02, 2018 Feb NEWA
 >A> AB EQ 5MG BASE A203966 002 Mar 02, 2018 Feb NEWA
 >A> AB EQ 10MG BASE A203966 003 Mar 02, 2018 Feb NEWA
 >A> AB EQ 20MG BASE A203966 004 Mar 02, 2018 Feb NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL
 BYVALSON
 +! ALLERGAN SALES LLC EQ 5MG BASE; 80MG N206302 001 Jun 03, 2016 Jan CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
 NEFAZODONE HYDROCHLORIDE
 @ FOSUN PHARMA 50MG A076302 001 Sep 16, 2003 Jan CAHN
 @ 100MG A076302 002 Sep 16, 2003 Jan CAHN
 @ 150MG A076302 003 Sep 16, 2003 Jan CAHN
 @ 200MG A076302 004 Sep 16, 2003 Jan CAHN
 @ 250MG A076302 005 Sep 16, 2003 Jan CAHN

NEOSTIGMINE METHYLSULFATESOLUTION; INTRAVENOUS
BLOXIVERZ

>A>	AP	+	!	AVADEL LEGACY	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb	CAHN
>A>	AP	+	!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb	CAHN
>D>	AP	+	!	ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb	CAHN
>D>	AP	+	!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb	CAHN

NEVIRAPINETABLET; ORAL
NEVIRAPINE

@ TECH ORGANIZED 200MG

A203176 001 May 22, 2012 Jan DISC

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

@ APOTEX INC 400MG

A205258 001 Apr 03, 2014 Jan DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB AUROBINDO PHARMA LTD 500MG

A209236 001 Feb 01, 2018 Jan NEWA

AB 750MG

A209236 002 Feb 01, 2018 Jan NEWA

AB 1GM

A209236 003 Feb 01, 2018 Jan NEWA

NITROGLYCERINOINTMENT; INTRA-ANAL
RECTIV

+! ALLERGAN SALES LLC 0.4%

N021359 001 Jun 21, 2011 Jan CAHN

TABLET; SUBLINGUAL

NITROGLYCERIN

AB GLENMARK PHARMS SA 0.3MG

A206391 001 Sep 19, 2017 Jan CAHN

AB 0.4MG

A206391 002 Sep 19, 2017 Jan CAHN

AB 0.6MG

A206391 003 Sep 19, 2017 Jan CAHN

NYSTATIN

OINTMENT; TOPICAL

NYSTATIN

@ G AND W LABS INC 100,000 UNITS/GM

A209114 001 Oct 06, 2017 Jan DISC

SUSPENSION; ORAL

NYSTATIN

@ G AND W LABS INC 100,000 UNITS/ML

A062349 001 Jul 14, 1982 Jan DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>A> AT AMNEAL PHARMS LLC 100,000 UNITS/GM; 0.1%

A209990 001 Feb 15, 2018 Feb NEWA

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT STRIDES PHARMA 100,000 UNITS/GM; 0.1%

A210077 001 Jan 29, 2018 Jan NEWA

ORITAVANCIN DIPHOSPHATE

POWDER; IV (INFUSION)

ORBACTIV

+! MELINTA EQ 400MG BASE/VIAL

N206334 001 Aug 06, 2014 Jan CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

>A> AB HETERO LABS LTD III EQ 30MG BASE

A209438 001 Feb 23, 2018 Feb NEWA

>A> AB EQ 45MG BASE

A209438 002 Feb 23, 2018 Feb NEWA

>A> AB EQ 75MG BASE

A209438 003 Feb 23, 2018 Feb NEWA

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

>A> AB LUPIN ATLANTIS EQ 6MG BASE/ML

A208347 001 Feb 20, 2018 Feb NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

>A> AP ACTAVIS LLC 50MG/10ML (5MG/ML)

A204880 001 Mar 05, 2018 Feb NEWA

>A> AP 100MG/20ML (5MG/ML)

A204880 002 Mar 05, 2018 Feb NEWA

OXYBUTYNIN CHLORIDE

	TABLET, EXTENDED RELEASE;ORAL							
>D>		DITROPAN XL						
>D>	AB	+ JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998	Feb	DISC
>A>		+ @	5MG	N020897	001	Dec 16, 1998	Feb	DISC
>D>	AB	+	10MG	N020897	002	Dec 16, 1998	Feb	DISC
>A>		+ @	10MG	N020897	002	Dec 16, 1998	Feb	DISC
>D>	AB	+!	15MG	N020897	003	Jun 22, 1999	Feb	DISC
>A>		+ @	15MG	N020897	003	Jun 22, 1999	Feb	DISC
	OXYBUTYNIN CHLORIDE							
>D>	AB	MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Feb	CHRS
>A>	AB	!	15MG	A076644	002	May 10, 2007	Feb	CHRS

OXYMORPHONE HYDROCHLORIDE

	TABLET;ORAL							
	OXYMORPHONE HYDROCHLORIDE							
AB		ASCENT PHARMS INC	5MG	A210175	001	Feb 02, 2018	Jan	NEWA
AB			10MG	A210175	002	Feb 02, 2018	Jan	NEWA

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

	OINTMENT;OPHTHALMIC							
	TERRAMYCIN W/ POLYMYXIN B SULFATE							
>D>	!	CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015	001		Feb	CMS2
>A>	!		EQ 5MG BASE/GM;10,000 UNITS/GM	N061015	001		Feb	CMS2

PEMOLINE

	TABLET;ORAL							
	PEMOLINE							
	@	FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999	Jan	CAHN
	@		37.5MG	A075286	002	Jun 30, 1999	Jan	CAHN
	@		75MG	A075286	003	Jun 30, 1999	Jan	CAHN

PENICILLIN G BENZATHINE

	INJECTABLE; INJECTION							
	PERMAPEN							
>D>	BC	CASPER PHARMA LLC	600,000 UNITS/ML	A060014	001		Feb	CMS2
>A>	BC		600,000 UNITS/ML	N060014	001		Feb	CMS2

PERINDOPRIL ERBUMINE

	TABLET;ORAL							
	PERINDOPRIL ERBUMINE							
	@	APOTEX	2MG	A090463	001	Aug 30, 2010	Jan	DISC
	@		4MG	A090463	002	Aug 30, 2010	Jan	DISC
	@		8MG	A090463	003	Aug 30, 2010	Jan	DISC

PHENTERMINE HYDROCHLORIDE

	CAPSULE;ORAL							
	PHENTERMINE HYDROCHLORIDE							
	@	ELITE LABS INC	15MG	A040460	001	Jan 14, 2003	Jan	CAHN

PHENYLBUTAZONE

	CAPSULE;ORAL							
	PHENYLBUTAZONE							
	@	FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982	Jan	CAHN
	TABLET;ORAL							
	PHENYLBUTAZONE							
	@	FOSUN PHARMA	100MG	A084339	001		Jan	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

	SYRUP;ORAL							
	PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE							
AA	!	VINTAGE	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jan	CHRS
		PROMETH VC PLAIN						
	@	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jan	DISC

PHENYTOIN

SUSPENSION;ORAL
PHENYTOIN

AB	WOCKHARDT BIO AG	125MG/5ML	A040420	001	Apr 19, 2002	Jan CAHN
----	------------------	-----------	---------	-----	--------------	----------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP	WOCKHARDT BIO AG	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan CPOT
----	------------------	--------------------------------------	---------	-----	--------------	----------

PIROXICAM

CAPSULE;ORAL
PIROXICAM

>A>	AB	LABORATORIOS CINFA	10MG	A208991	001	Feb 21, 2018	Feb NEWA
>A>	AB		20MG	A208991	002	Feb 21, 2018	Feb NEWA
>D>	AB	+ MICRO LABS	10MG	A206152	001	Dec 29, 2017	Feb CRLD
>A>	AB		10MG	A206152	001	Dec 29, 2017	Feb CRLD
>D>	AB	+	20MG	A206152	002	Dec 29, 2017	Feb CRLD
>A>	AB		20MG	A206152	002	Dec 29, 2017	Feb CRLD
AB	STRIDES PHARMA		10MG	A210347	001	Jan 26, 2018	Jan NEWA
AB			20MG	A210347	002	Jan 26, 2018	Jan NEWA

POLIDOCANOL

SOLUTION; INTRAVENOUS
VARITHENA

+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Jan CDFR
----	-----------	-------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL
K-TAB

AB3	+ ABBVIE	10MEQ	N018279	001		Jan CTEC
AB2	+!	20MEQ	N018279	003	Nov 25, 2013	Jan CTEC
	POTASSIUM CHLORIDE					
AB3	PADDOCK LLC	10MEQ	A209688	001	Jan 12, 2018	Jan NEWA
AB2		20MEQ	A209688	002	Jan 12, 2018	Jan NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

AB	MOUNTAIN	5MEQ	A077440	001	Jun 09, 2006	Jan CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Jan CAHN
>A>	AB	TEVA PHARMS USA INC	A209758	001	Mar 05, 2018	Feb NEWA
>A>	AB		A209758	002	Mar 05, 2018	Feb NEWA
>A>	AB		A209758	003	Mar 05, 2018	Feb NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL
PRASUGREL

AB	ACCORD HLTHCARE	EQ 5MG BASE	A205987	001	Feb 02, 2018	Jan NEWA
AB		EQ 10MG BASE	A205987	002	Feb 02, 2018	Jan NEWA
AB	USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Jan CAHN
AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Jan CAHN

PREDNISOLONE

TABLET;ORAL
PREDNISOLONE
@ FOSUN PHARMA

		5MG	A080339	001		Jan CAHN
--	--	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL
PREDNISOLONE SODIUM PHOSPHATE

AA	!	WOCKHARDT BIO AG	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan CAHN
----	---	------------------	------------------	---------	-----	--------------	----------

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
ALCAINE

>A>	AT	!	ALCON LABS INC	0.5%	A080027	001	Feb CAHN
>D>	AT	!	NOVARTIS PHARMS CORP	0.5%	A080027	001	Feb CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
 PROPRANOLOL HYDROCHLORIDE

@ FOSUN PHARMA 1MG/ML A076400 001 Feb 26, 2003 Jan CAHN

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@ YAOPHARMA CO LTD 10MG A070663 001 Jun 13, 1986 Jan CAHN
 @ 20MG A070664 001 Jun 13, 1986 Jan CAHN
 @ 40MG A070665 001 Jun 13, 1986 Jan CAHN
 @ 60MG A070666 001 Oct 10, 1986 Jan CAHN
 @ 80MG A070667 001 Jun 13, 1986 Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

@ FOSUN PHARMA 60MG; 2.5MG A088602 001 Apr 11, 1985 Jan CAHN

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+! VYERA PHARMS LLC 25MG N008578 001 Jan CAHN

QUAZEPAM

TABLET; ORAL

DORAL

>D> @ CUTIS HEALTH LLC 7.5MG N018708 003 Feb 26, 1987 Feb CAHN
 >D> +! 15MG N018708 001 Dec 27, 1985 Feb CAHN
 >A> @ GALT PHARMS 7.5MG N018708 003 Feb 26, 1987 Feb CAHN
 >A> +! 15MG N018708 001 Dec 27, 1985 Feb CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@ YAOPHARMA CO LTD EQ 5MG BASE A076803 001 Mar 02, 2005 Jan CAHN
 @ EQ 10MG BASE A076803 002 Mar 02, 2005 Jan CAHN
 @ EQ 20MG BASE A076803 003 Mar 02, 2005 Jan CAHN
 @ EQ 40MG BASE A076803 004 Mar 02, 2005 Jan CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

@ G AND W LABS INC 300MG A040045 001 Jun 30, 1994 Jan DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

>D> + AVADEL PHARMS 5MG N204736 001 Mar 26, 2013 Feb CAHN
 >D> +! 10MG N204736 002 Mar 26, 2013 Feb CAHN
 >A> + CERECOR INC 5MG N204736 001 Mar 26, 2013 Feb CAHN
 >A> +! 10MG N204736 002 Mar 26, 2013 Feb CAHN

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ YAOPHARMA CO LTD 1.25MG A077514 001 Jun 18, 2008 Jan CAHN
 @ 2.5MG A077514 002 Jun 18, 2008 Jan CAHN
 @ 5MG A077514 003 Jun 18, 2008 Jan CAHN
 @ 10MG A077514 004 Jun 18, 2008 Jan CAHN

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

REMIFENTANIL HYDROCHLORIDE

AP FRESENIUS KABI USA EQ 1MG BASE/VIAL A206223 001 Jan 16, 2018 Jan NEWA
 AP EQ 2MG BASE/VIAL A206223 002 Jan 16, 2018 Jan NEWA
 AP EQ 5MG BASE/VIAL A206223 003 Jan 16, 2018 Jan NEWA

ULTIVA

AP + MYLAN INSTITUTIONAL EQ 1MG BASE/VIAL N020630 001 Jul 12, 1996 Jan CFTG
 AP + EQ 2MG BASE/VIAL N020630 002 Jul 12, 1996 Jan CFTG
 AP +! EQ 5MG BASE/VIAL N020630 003 Jul 12, 1996 Jan CFTG

RISPERIDONE

	TABLET;ORAL						
	RISPERIDONE						
AB	RENATA	0.25MG	A 078707	001	Dec 29, 2008	Jan	CAHN
AB		0.5MG	A 078707	002	Dec 29, 2008	Jan	CAHN
AB		1MG	A 078707	003	Dec 29, 2008	Jan	CAHN
AB		2MG	A 078707	004	Dec 29, 2008	Jan	CAHN
AB		3MG	A 078707	005	Dec 29, 2008	Jan	CAHN
AB		4MG	A 078707	006	Dec 29, 2008	Jan	CAHN

ROFLUMILAST

	TABLET;ORAL						
	DALIRESP						
	+ ASTRAZENECA PHARMS	250MCG	N 022522	002	Jan 23, 2018	Jan	NEWA

ROPINIROLE HYDROCHLORIDE

	TABLET;ORAL						
	ROPINIROLE HYDROCHLORIDE						
	@ G AND W LABS INC	EQ 0.25MG BASE	A 077460	001	May 05, 2008	Jan	DISC
	@	EQ 0.5MG BASE	A 077460	002	May 05, 2008	Jan	DISC
	@	EQ 1MG BASE	A 077460	003	May 05, 2008	Jan	DISC
	@	EQ 2MG BASE	A 077460	004	May 05, 2008	Jan	DISC
	@	EQ 3MG BASE	A 077460	005	May 05, 2008	Jan	DISC
	@	EQ 4MG BASE	A 077460	006	May 05, 2008	Jan	DISC
	@	EQ 5MG BASE	A 077460	007	May 19, 2008	Jan	DISC

SERTRALINE HYDROCHLORIDE

	TABLET;ORAL						
	SERTRALINE HYDROCHLORIDE						
	@ FOSUN PHARMA	EQ 25MG BASE	A 077713	001	Feb 06, 2007	Jan	CAHN
	@	EQ 50MG BASE	A 077713	002	Feb 06, 2007	Jan	CAHN
	@	EQ 100MG BASE	A 077713	003	Feb 06, 2007	Jan	CAHN

SIMVASTATIN

	TABLET;ORAL						
	SIMVASTATIN						
	@ YAOPHARMA CO LTD	5MG	A 077766	001	Dec 20, 2006	Jan	CAHN
	@	10MG	A 077766	002	Dec 20, 2006	Jan	CAHN
	@	20MG	A 077766	003	Dec 20, 2006	Jan	CAHN
	@	40MG	A 077766	004	Dec 20, 2006	Jan	CAHN
	@	80MG	A 077766	005	Dec 20, 2006	Jan	CAHN

SINECATECHINS

	OINTMENT;TOPICAL						
	VEREGEN						
	+! FOUGERA PHARMS INC	15%	N 021902	001	Oct 31, 2006	Jan	CAHN

SODIUM CHLORIDE

	INJECTABLE;INJECTION							
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
>D>	AP	+! HOSPIRA	9MG/ML	N 019217	001	Jul 13, 1984	Feb	CAHN
>A>	AP	+! ICU MEDICAL INC	9MG/ML	N 019217	001	Jul 13, 1984	Feb	CAHN

SODIUM FLUORIDE F-18

	INJECTABLE;INTRAVENOUS							
	SODIUM FLUORIDE F-18							
>A>	AP	SOFIE	10-200mCi/ML	A 203592	001	Aug 18, 2015	Feb	CAHN
>D>	AP	ZEVACOR PHARMA INC	10-200mCi/ML	A 203592	001	Aug 18, 2015	Feb	CAHN

>A> SOMATROPIN

>A>	INJECTABLE;INJECTION							
>A>	BIO-TROPIN							
>A>	@ FERRING	4.8MG/VIAL	N 019774	001	May 25, 1995	Feb	CAIN	
>A>	ZOMACTON							
>A>	BX	+! FERRING	5MG/VIAL	N 019774	002	Jan 04, 2002	Feb	CAIN
>A>	+		10MG/VIAL	N 019774	003	Mar 07, 2012	Feb	CAIN

>D>	<u>SOMATROPIN RECOMBINANT</u>								
>D>	INJECTABLE; INJECTION								
>D>	BIO-TROPIN								
>D>	@	FERRING	4.8MG/VIAL		N019774	001	May 25, 1995	Feb	CAIN
>D>	ZOMACTON								
>D>	BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Feb	CAIN
>D>			+	10MG/VIAL	N019774	003	Mar 07, 2012	Feb	CAIN
	<u>SUCRALFATE</u>								
	SUSPENSION; ORAL								
	CARAFATE								
	+	!	ALLERGAN SALES LLC	1GM/10ML	N019183	001	Dec 16, 1993	Jan	CAHN
	TABLET; ORAL								
	CARAFATE								
AB	+	!	ALLERGAN SALES LLC	1GM	N018333	001		Jan	CAHN
	<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>								
	TABLET; ORAL								
	SULFAMETHOXAZOLE AND TRIMETHOPRIM								
	@	FOSUN PHARMA	400MG; 80MG		A070889	001	Nov 13, 1986	Jan	CAHN
	@		400MG; 80MG		N018598	003	May 19, 1982	Jan	CAHN
	@		800MG; 160MG		A070890	001	Nov 13, 1986	Jan	CAHN
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH								
	@	FOSUN PHARMA	800MG; 160MG		N018598	004	May 19, 1982	Jan	CAHN
	<u>SULINDAC</u>								
	TABLET; ORAL								
	SULINDAC								
	@	FOSUN PHARMA	150MG		A072712	001	Aug 30, 1991	Jan	CAHN
	@		200MG		A072713	001	Aug 30, 1991	Jan	CAHN
	<u>SUMATRIPTAN SUCCINATE</u>								
	TABLET; ORAL								
	SUMATRIPTAN SUCCINATE								
	@	FOSUN PHARMA	EQ 25MG BASE		A076976	001	Aug 10, 2009	Jan	CAHN
	@		EQ 50MG BASE		A076976	002	Aug 10, 2009	Jan	CAHN
	@		EQ 100MG BASE		A076976	003	Aug 10, 2009	Jan	CAHN
	<u>TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT</u>								
	INJECTABLE; INJECTION								
	PULMOLITE								
>D>	BS	+	JUBILANT DRAXIMAGE	N/A	N017776	001		Feb	DISC
>A>			+ @	N/A	N017776	001		Feb	DISC
	<u>TECHNETIUM TC-99M MEDRONATE KIT</u>								
	INJECTABLE; INJECTION								
	CIS-MDP								
			PHARMALUCENCE	N/A	N018124	001		Jan	CTEC
	MDP-BRACCO								
	@	CARDINAL HEALTH 414	N/A		N018107	001		Jan	DISC
	<u>TECHNETIUM TC-99M PENTETATE KIT</u>								
	INJECTABLE; INJECTION								
	DTPA								
	+	!	JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Jan	CAHN
	<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>								
>A>	SOLUTION; INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC								
>A>	RADIOGENIX SYSTEM								
>A>	+		NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018	Feb	NEWA
	<u>TENOFOVIR DISOPROXIL FUMARATE</u>								
	TABLET; ORAL								
	TENOFOVIR DISOPROXIL FUMARATE								
AB			AUROBINDO PHARMA LTD	150MG	A090647	001	Jan 26, 2018	Jan	NEWA
AB				200MG	A090647	002	Jan 26, 2018	Jan	NEWA
AB				250MG	A090647	003	Jan 26, 2018	Jan	NEWA
AB				300MG	A090647	004	Jan 26, 2018	Jan	NEWA
AB			CIPLA LTD	300MG	A078800	001	Jan 26, 2018	Jan	NEWA
AB			HETERO LABS LTD III	300MG	A090636	001	Jan 26, 2018	Jan	NEWA
>A>	AB		LAURUS LABS PVT	300MG	A209550	001	Feb 26, 2018	Feb	NEWA

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	MACLEODS PHARMS LTD	300MG	A203232	001	Jan 26, 2018	Jan NEWA	
>A>	AB	QILU TIANHE	200MG	A209498	001	Mar 02, 2018	Feb NEWA
>A>	AB		250MG	A209498	002	Mar 02, 2018	Feb NEWA
>A>	AB		300MG	A209498	003	Mar 02, 2018	Feb NEWA
AB	STRIDES PHARMA	300MG	A090742	001	Jan 26, 2018	Jan NEWA	
AB	TEVA PHARMS USA	150MG	A091612	002	Jan 26, 2018	Jan NEWA	
AB		200MG	A091612	003	Jan 26, 2018	Jan NEWA	
AB		250MG	A091612	004	Jan 26, 2018	Jan NEWA	
VIREAD							
AB	+ GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Jan CFTG	
AB	+	200MG	N021356	003	Jan 18, 2012	Jan CFTG	
AB	+	250MG	N021356	004	Jan 18, 2012	Jan CFTG	

TERCONAZOLE

CREAM;VAGINAL

>D>	TERAZOL 7							
>D>	AB	+!	JANSSEN PHARMS	0.4%	N019579	001	Dec 31, 1987	Feb DISC
>A>		+	@	0.4%	N019579	001	Dec 31, 1987	Feb DISC
TERCONAZOLE								
>D>	AB		TARO	0.4%	A076043	001	Jan 19, 2005	Feb CHRS
>A>	AB	!		0.4%	A076043	001	Jan 19, 2005	Feb CHRS
SUPPOSITORY;VAGINAL								
>D>	TERAZOL 3							
>D>	AB	+!	JANSSEN PHARMS	80MG	N019641	001	May 24, 1988	Feb DISC
>A>		+	@	80MG	N019641	001	May 24, 1988	Feb DISC
TERCONAZOLE								
>D>	AB		PERRIGO NEW YORK	80MG	A077149	001	Mar 17, 2006	Feb CHRS
>A>	AB	!		80MG	A077149	001	Mar 17, 2006	Feb CHRS

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

	@ ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jan DISC
	@	50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jan DISC
SOLUTION, METERED;TRANSDERMAL						
TESTOSTERONE						
AT	CIPLA LTD	30MG/1.5ML ACTUATION	A209533	001	Jan 29, 2018	Jan NEWA

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

AB	NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Jan CTEC
AB		200MG	A087400	004	Feb 21, 1985	Jan CTEC

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

	@ FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983	Jan CAHN
	@	25MG	A088133	001	Aug 30, 1983	Jan CAHN
	@	50MG	A088134	001	Aug 30, 1983	Jan CAHN
	@	100MG	A088135	001	Nov 20, 1984	Jan CAHN
	@	200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTHIXENE

CAPSULE;ORAL

NAVANE

+	@ PFIZER	1MG	N016584	001		Jan CRLD
+	@	2MG	N016584	002		Jan CRLD
+	@	5MG	N016584	003		Jan CRLD
+	@	10MG	N016584	004		Jan CRLD
+	@	20MG	N016584	005		Jan CRLD

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

	@ YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Jan CAHN
	@	250MG	A075326	001	Aug 20, 1999	Jan CAHN

TIGECYCLINE

POWDER; IV (INFUSION)

TIGECYCLINE

ACCORD HLTHCARE INC 50MG/VIAL

N208744 001 Jan 18, 2018 Jan NEWA

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC

AT + ATON EQ 0.25% BASE
AT1 + EQ 0.5% BASEN018086 001 Jan CMFD
N018086 002 Jan CMFD

TABLET; ORAL

TIMOLOL MALEATE

@ YAOPHARMA CO LTD 5MG

A072550 001 Apr 13, 1989 Jan CAHN

@ 10MG

A072551 001 Apr 13, 1989 Jan CAHN

@ 20MG

A072552 001 Apr 13, 1989 Jan CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

>A> AB ZYDUS PHARMS USA INC EQ 2MG BASE

A208187 001 Mar 09, 2018 Feb NEWA

>A> AB EQ 4MG BASE

A208187 002 Mar 09, 2018 Feb NEWA

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ YAOPHARMA CO LTD 100MG

A071633 001 Dec 09, 1987 Jan CAHN

@ 250MG

A070289 001 Mar 13, 1986 Jan CAHN

@ 500MG

A070290 001 Mar 13, 1986 Jan CAHN

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

@ YAOPHARMA CO LTD 500MG

A086574 001 Jan CAHN

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA EQ 400MG BASE

A073462 001 Apr 30, 1992 Jan CAHN

TABLET; ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA EQ 200MG BASE

A073588 001 Jul 31, 1992 Jan CAHN

@ EQ 600MG BASE

A074002 001 Sep 27, 1993 Jan CAHN

TOPIRAMATE

CAPSULE; ORAL

TOPIRAMATE

@ FOSUN PHARMA 15MG

A079206 001 Oct 14, 2009 Jan CAHN

@ 25MG

A079206 002 Oct 14, 2009 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

@ FOSUN PHARMA 50MG

A075968 001 Jun 25, 2002 Jan CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

@ FOSUN PHARMA 100MG

A072483 001 Apr 30, 1990 Jan CAHN

TRIAMCINOLONE ACETONIDE

SPRAY; TOPICAL

KENALOG

>D> AT +! RANBAXY LABS LTD 0.147MG/GM

N012104 001 Feb CAHN

>A> AT +! SUN PHARM INDS INC 0.147MG/GM

N012104 001 Feb CAHN

TRIENTINE HYDROCHLORIDE

	CAPSULE;ORAL								
	SYPRINE								
AB	+!	ATON	250MG		N019194	001	Nov 08, 1985	Jan	CFTG
		TRIENTINE HYDROCHLORIDE							
AB		WATSON LABS TEVA	250MG		A207567	001	Feb 07, 2018	Jan	NEWA

TRIFLUOPERAZINE HYDROCHLORIDE

	CONCENTRATE;ORAL								
	TRIFLUOPERAZINE HYDROCHLORIDE								
	@	FOSUN PHARMA	EQ 10MG BASE/ML		A085787	001	Apr 15, 1982	Jan	CAHN

VANCOMYCIN HYDROCHLORIDE

	CAPSULE;ORAL								
	VANCOMYCIN HYDROCHLORIDE								
>D>	AB	FRESENIUS KABI USA	EQ 125MG BASE		A065453	001	Jun 18, 2012	Feb	DISC
>A>		@	EQ 125MG BASE		A065453	001	Jun 18, 2012	Feb	DISC
>D>	AB		EQ 250MG BASE		A065453	002	Jun 18, 2012	Feb	DISC
>A>		@	EQ 250MG BASE		A065453	002	Jun 18, 2012	Feb	DISC
	FOR SOLUTION;ORAL								
	FIRVANQ KIT								
	+!	RXMTM THERAPS LLC	EQ 25MG BASE/ML		N208910	001	Jan 26, 2018	Jan	NEWA
	+!		EQ 50MG BASE/ML		N208910	002	Jan 26, 2018	Jan	NEWA

VARENICLINE TARTRATE

	TABLET;ORAL								
	CHANTIX								
>A>	+	PF PRISM CV	EQ 0.5MG BASE		N021928	001	May 10, 2006	Feb	CAHN
>A>	+!		EQ 1MG BASE		N021928	002	May 10, 2006	Feb	CAHN
>D>	+	PFIZER INC	EQ 0.5MG BASE		N021928	001	May 10, 2006	Feb	CAHN
>D>	+!		EQ 1MG BASE		N021928	002	May 10, 2006	Feb	CAHN

VENLAFAXINE HYDROCHLORIDE

	TABLET;ORAL								
	VENLAFAXINE HYDROCHLORIDE								
	@	FOSUN PHARMA	EQ 25MG BASE		A077515	001	Jun 13, 2008	Jan	CAHN
	@		EQ 37.5MG BASE		A077515	002	Jun 13, 2008	Jan	CAHN
	@		EQ 50MG BASE		A077515	003	Jun 13, 2008	Jan	CAHN
	@		EQ 75MG BASE		A077515	004	Jun 13, 2008	Jan	CAHN
	@		EQ 100MG BASE		A077515	005	Jun 13, 2008	Jan	CAHN

VERAPAMIL HYDROCHLORIDE

	SOLUTION;INTRAVENOUS								
	VERAPAMIL HYDROCHLORIDE								
AP	!	HOSPIRA	5MG/2ML (2.5MG/ML)		A070738	001	May 06, 1987	Jan	CPOT
	TABLET;ORAL								
	VERAPAMIL HYDROCHLORIDE								
	@	YAOPHARMA CO LTD	40MG		A073168	001	Jul 31, 1992	Jan	CAHN
	@		80MG		A071423	001	May 24, 1988	Jan	CAHN
	@		120MG		A071424	001	May 25, 1988	Jan	CAHN

VIGABATRIN

	FOR SOLUTION;ORAL								
	VIGABATRIN								
>A>	AA	AMNEAL PHARMS	500MG/PACKET		A210155	001	Mar 13, 2018	Feb	NEWA

VILAZODONE HYDROCHLORIDE

	TABLET;ORAL								
	VIIBRYD								
	+!	ALLERGAN SALES LLC	10MG		N022567	001	Jan 21, 2011	Jan	CAHN
	+		20MG		N022567	002	Jan 21, 2011	Jan	CAHN
	+		40MG		N022567	003	Jan 21, 2011	Jan	CAHN

WARFARIN SODIUM

	TABLET;ORAL								
	WARFARIN SODIUM								
	@	YAOPHARMA CO LTD	1MG		A040196	001	Sep 30, 1997	Jan	CAHN
	@		2MG		A040196	002	Sep 30, 1997	Jan	CAHN
	@		2.5MG		A040196	003	Sep 30, 1997	Jan	CAHN
	@		3MG		A040196	008	Jul 26, 2000	Jan	CAHN
	@		4MG		A040196	004	Sep 30, 1997	Jan	CAHN

TABLET;ORAL

WARFARIN SODIUM

@	5MG	A040196	005	Sep 30, 1997	Jan	CAHN
@	6MG	A040196	009	Jul 26, 2000	Jan	CAHN
@	7.5MG	A040196	006	Sep 30, 1997	Jan	CAHN
@	10MG	A040196	007	Sep 30, 1997	Jan	CAHN

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan	CAHN
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan	CAHN
>D>	! SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb	DISC
>A>	@	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb	DISC

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

>A>	@ AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Feb	CAHN
>A>	@	50MG	A077645	003	Sep 29, 2006	Feb	CAHN
>A>	@	100MG	A077645	001	Dec 22, 2005	Feb	CAHN
>D>	@ DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006	Feb	CAHN
>D>	@	50MG	A077645	003	Sep 29, 2006	Feb	CAHN
>D>	@	100MG	A077645	001	Dec 22, 2005	Feb	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL
ACEPHEN

@ G AND W LABS	325MG	N018060	003	Dec 18, 1986	Jan DISC
@	650MG	N018060	002		Jan DISC

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007	Feb CAHN
>A>		10MG	A077946	002	Dec 27, 2007	Feb CAHN
>D>	SANDOZ	5MG	A077946	001	Dec 27, 2007	Feb CAHN
>D>		10MG	A077946	002	Dec 27, 2007	Feb CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	PLD ACQUISITIONS	5MG;120MG	A077991	001	Mar 05, 2008	Feb CAHN
>D>	SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008	Feb CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL
CHLORAPREP ONE-STEP

>A>	+! BECTON DICKINSON CO	2%;70% (1ML)	N020832	008	Oct 23, 2008	Feb NEWA
-----	------------------------	--------------	---------	-----	--------------	----------

CLEMASTINE FUMARATE

TABLET;ORAL
CLEMASTINE FUMARATE

PLD ACQUISITIONS LLC	1.34MG	A073458	001	Oct 31, 1993	Jan CAHN
----------------------	--------	---------	-----	--------------	----------

CLOTRIMAZOLE

CREAM, TABLET;TOPICAL, VAGINAL
MYCELEX-7 COMBINATION PACK

>D>	BAYER HEALTHCARE LLC	1%,100MG	N020389	002	Jun 23, 1994	Feb DISC
>A>	@	1%,100MG	N020389	002	Jun 23, 1994	Feb DISC

IBUPROFEN

TABLET;ORAL
IBUPROFEN

@ P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986	Jan CAHN
-------------------	-------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018	Jan NEWA
--------------------	-----	---------	-----	--------------	----------

LORATADINE

TABLET;ORAL
LORATADINE

PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003	Jan CAHN
----------------------	------	---------	-----	--------------	----------

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
MICONAZOLE 7 COMBINATION PACK

@ G AND W LABS	2%,100MG	A076585	001	Mar 26, 2004	Jan DISC
----------------	----------	---------	-----	--------------	----------

NAPROXEN SODIUM

TABLET;ORAL
NAPROXEN SODIUM

@ PLD ACQUISITIONS LLC	EQ 200MG BASE	A074646	001	Jan 13, 1997	Jan CAHN
------------------------	---------------	---------	-----	--------------	----------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
THRIVE

>A>	GLAXOSMITHKLINE CONS	EQ 2MG BASE	A077658	001	Jun 19, 2007	Feb CAHN
>A>		EQ 4MG BASE	A077656	001	Jun 19, 2007	Feb CAHN
>D>	NOVARTIS	EQ 2MG BASE	A077658	001	Jun 19, 2007	Feb CAHN
>D>		EQ 4MG BASE	A077656	001	Jun 19, 2007	Feb CAHN

TROCHE/LOZENGE;ORAL

>D> COMMIT

>D> + GLAXOSMITHKLINE CONS EQ 2MG BASE N021330 001 Oct 31, 2002 Feb CTNA

>D> +! EQ 4MG BASE N021330 002 Oct 31, 2002 Feb CTNA

>A> NICORETTE

>A> + GLAXOSMITHKLINE CONS EQ 2MG BASE N021330 001 Oct 31, 2002 Feb CTNA

>A> +! EQ 4MG BASE N021330 002 Oct 31, 2002 Feb CTNA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>A> VIVIMED GLOBAL EQ 75MG BASE A209160 001 Mar 05, 2018 Feb NEWA

>A> EQ 150MG BASE A209161 001 Feb 22, 2018 Feb NEWA

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

>A> +! GLAXOSMITHKLINE CONS 1% N021958 001 Jul 24, 2006 Feb CAHN

>D> +! NOVARTIS 1% N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL AT

>A> +! GLAXOSMITHKLINE CONS 1% N021124 001 Mar 17, 2000 Feb CAHN

>D> +! NOVARTIS 1% N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

>A> +! GLAXOSMITHKLINE CONS 1% N021124 002 Mar 17, 2000 Feb CAHN

>D> +! NOVARTIS 1% N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY 2018

NO FEBRUARY 2018 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	001				>A> I-768	Feb 26, 2021
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	002				>A> I-768	Feb 26, 2021
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	003				>A> I-768	Feb 26, 2021
<u>ABEMACICLIB - VERZENIO</u>						
N 208716	004				>A> I-768	Feb 26, 2021
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	001	>A> 8822438	Aug 24, 2027	U-1579	>A> I-765	Feb 07, 2021
		>A> 8822438	Aug 24, 2027	U-1580		
		>A> 8822438	Aug 24, 2027	U-2235		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	002	>A> 8822438	Aug 24, 2027	U-1579	>A> I-765	Feb 07, 2021
		>A> 8822438	Aug 24, 2027	U-1580		
		>A> 8822438	Aug 24, 2027	U-2235		
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292	001				I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292	002				I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292	003				I-763	Jan 12, 2021
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	001	9867791	Dec 02, 2030	U-2106		
		9867792	Dec 02, 2030	U-2106		
		9867793	Dec 02, 2030	U-2106		
		9877933	Dec 02, 2030	U-2224		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	002	9867791	Dec 02, 2030	U-2106		
		9867792	Dec 02, 2030	U-2106		
		9867793	Dec 02, 2030	U-2106		
		9877933	Dec 02, 2030	U-2224		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	001	>A> 8252331	Mar 13, 2030	DP		
		>A> 8574626	Nov 28, 2025	DP	U-20	
		>A> RE39069	May 29, 2018	DP		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	002	>A> 8252331	Mar 13, 2030	DP		
		>A> 8574626	Nov 28, 2025	DP	U-20	
		>A> RE39069	May 29, 2018	DP		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	003	>A> 8252331	Mar 13, 2030	DP		
		>A> 8574626	Nov 28, 2025	DP	U-20	
		>A> RE39069	May 29, 2018	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	>A> 9867863	Dec 16, 2029	U-2231			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	>A> 9867863	Dec 16, 2029	U-2231			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	>A> 8445507	Sep 15, 2030	DS DP U-2237		>A> NCE	Feb 14, 2023
	>A> 8802689	Mar 27, 2027	U-2237			
	>A> 9388159	Mar 27, 2027	DS DP			
	>A> 9481663	Jun 04, 2033	DS DP U-2237			
	>A> 9884054	Sep 23, 2033	U-2237			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	>A> 9872854	May 29, 2034	U-2232			
	>A> 9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	>A> 9872854	May 29, 2034	U-2232			
	>A> 9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	>A> 9872854	May 29, 2034	U-2232			
	>A> 9872854	May 29, 2034	U-2233			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	>A> 6723351	Nov 10, 2018	U-2204			
	>A> 6723351	Nov 10, 2018	U-2229			
	>A> 6723351	Nov 10, 2018	U-573			
	>A> 6855339	Nov 10, 2018	U-2204			
	>A> 6855339	Nov 10, 2018	U-2229			
	>A> 6855339	Nov 10, 2018	U-617			
	>A> 6861076	Nov 10, 2018	U-2204			
	>A> 6861076	Nov 10, 2018	U-2229			
	>A> 6861076	Nov 10, 2018	U-617			
	>A> 6884439	Nov 10, 2018	U-2204			
	>A> 6884439	Nov 10, 2018	U-2229			
	>A> 6884439	Nov 10, 2018	U-651			
	>A> 6982096	Nov 10, 2018	U-2204			
	>A> 6982096	Nov 10, 2018	U-2229			
	>A> 6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	>A> 6723351	Nov 10, 2018	U-2204			
	>A> 6723351	Nov 10, 2018	U-2229			
	>A> 6723351	Nov 10, 2018	U-573			
	>A> 6855339	Nov 10, 2018	U-2204			
	>A> 6855339	Nov 10, 2018	U-2229			
	>A> 6855339	Nov 10, 2018	U-617			
	>A> 6861076	Nov 10, 2018	U-2204			
	>A> 6861076	Nov 10, 2018	U-2229			
	>A> 6861076	Nov 10, 2018	U-617			
	>A> 6884439	Nov 10, 2018	U-2204			
	>A> 6884439	Nov 10, 2018	U-2229			
	>A> 6884439	Nov 10, 2018	U-651			
	>A> 6982096	Nov 10, 2018	U-2204			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	>A> 6982096	Nov 10, 2018	U-2229			
	>A> 6982096	Nov 10, 2018	U-651			
	>A> 8273379	Nov 10, 2018	U-2204			
	>A> 8273379	Nov 10, 2018	U-2229			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001					M-158 NPP PED PED	Mar 12, 2018 Mar 12, 2018 Sep 12, 2018 Sep 12, 2018
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002					M-158 NPP PED PED	Mar 12, 2018 Mar 12, 2018 Sep 12, 2018 Sep 12, 2018
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	>A> 7112592	Feb 24, 2022	DS DP U-2244			
	>A> 7112592	Feb 24, 2022	DS DP U-282			
	>A> 8178554	Jul 24, 2021	DS DP U-2245			
	>A> 8178554	Jul 24, 2021	DS DP U-282			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	>A> 5998402	Apr 04, 2019	DS DP U-594			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	8791270	Jan 12, 2026	DP U-1790			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	>A> 9877974	Aug 31, 2030	DP U-1858			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	>A> 6642245	Nov 04, 2020	U-257		>A> NCE	Feb 07, 2023
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 7390791	May 07, 2022	DS DP			
	>A> 7803788	Feb 02, 2022	U-257			
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 9216996	Dec 19, 2033	DS DP			
	>A> 9296769	Aug 15, 2032	DS DP U-257			
	>A> 9708342	Jun 19, 2035	DS DP			
	>A> 9732092	Dec 19, 2033	DS DP			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					>A> ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					>A> ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003					>A> ODE-163	Dec 19, 2024
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	8293742	Jul 14, 2030	U-2222			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	>A> 9907801	Apr 19, 2022	DP U-2239			
	>A> 9907802	Apr 19, 2022	DP U-2240			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	>A> 8387615	Mar 26, 2027	DP			
	>A> 8387615*PED	Sep 26, 2027				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	>A> 8387615	Mar 26, 2027	DP			
	>A> 8387615*PED	Sep 26, 2027				
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					NP	Nov 30, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					NP	Nov 30, 2020
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	9861644	Mar 14, 2034	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	>A> 7094427	May 29, 2022	DP U-1645	Y		
	>A> 9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	>A> 7094427	May 29, 2022	DP U-1645	Y		
	>A> 9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	>A> 7094427	May 29, 2022	DP U-1645	Y		
	>A> 9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	>A> 7094427	May 29, 2022	DP U-1645	Y		
	>A> 9901640	Dec 26, 2028	DP U-219			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9872906	Mar 14, 2034	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524 001					>A> M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524 002					>A> M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003					>A> M-221	Feb 14, 2021
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	>A> 9889115	Jun 23, 2019	U-1660			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	>A> 9891239	Sep 03, 2029	DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	>A> 9891239	Sep 03, 2029	DP U-257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	9867815	Feb 07, 2037	U-2225		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					ODE-162	Dec 22, 2024
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002					ODE-162	Dec 22, 2024
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					>A> ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					>A> ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					>A> ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					>A> ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					>A> ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					>A> ODE-164	Nov 09, 2024
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001					>A> M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002					>A> M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003					>A> M-222	Feb 06, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	>A> 6960346	Jul 03, 2023	DP		>A> NP	Feb 09, 2021
	>A> 7560120	Sep 05, 2022	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	>A> 6509376	Apr 01, 2018	DP			
	>A> 7320999	Oct 20, 2018	U-1384			
	>A> 7619001	Apr 01, 2018	U-1384			
	>A> 7803840	Apr 01, 2018	U-1385			
	>A> 8399514	Feb 07, 2028	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	>A> 6509376	Apr 01, 2018	DP			
	>A> 7320999	Oct 20, 2018	U-1384			
	>A> 7619001	Apr 01, 2018	U-1384			
	>A> 7803840	Apr 01, 2018	U-1385			
	>A> 8399514	Feb 07, 2028	U-1384			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9861607	May 18, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9861607	May 18, 2027	U-620			
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 001					>A> PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 002					>A> PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 003					>A> PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 091471 001					PC	Feb 14, 2018
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9877955	Jan 03, 2028	U-1969			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	>A> 9884092	Aug 18, 2026	U-1313			
	>A> 9884092	Aug 18, 2026	U-2154			
	>A> 9884092	Aug 18, 2026	U-2155			
	>A> 9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	>A> 9884092	Aug 18, 2026	U-1313			
	>A> 9884092	Aug 18, 2026	U-2154			
	>A> 9884092	Aug 18, 2026	U-2155			
	>A> 9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	>A> 9884092	Aug 18, 2026	U-1313			
	>A> 9884092	Aug 18, 2026	U-2154			
	>A> 9884092	Aug 18, 2026	U-2155			
	>A> 9884092	Aug 18, 2026	U-2156			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9814705	Jan 08, 2024	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001				>A> I-767		Feb 02, 2021
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	9750726	Nov 29, 2030	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	9730890	Jun 22, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001					>A> M-220	Feb 15, 2021
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9872837	Dec 21, 2031	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	>A> 9248229	Mar 12, 2034	DP			
	>A> 9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	>A> 9248229	Mar 12, 2034	DP			
	>A> 9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	>A> 9248229	Mar 12, 2034	DP			
	>A> 9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	>A> 9248229	Mar 12, 2034	DP			
	>A> 9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	>A> 9248229	Mar 12, 2034	DP			
	>A> 9731082	Apr 23, 2032	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	>A> 8021335	Oct 04, 2026	DP			
	>A> 8562564	Jan 24, 2026	DP			
	>A> 9180259	Jan 24, 2026	DP			
	>A> 9533102	Jan 24, 2026	DP			
	>A> 9629959	Jan 24, 2026	DP			
	>A> 9789257	Feb 11, 2034	DP			
	>A> 9844558	May 02, 2036	DP	U-2236		
	>A> RE44846	Aug 10, 2019	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2219	
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026			U-1491	
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031			U-1456	
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2228	
	9125889	Jun 03, 2031			U-1650	
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033			U-1456	
	9540382	Aug 18, 2033			U-1491	
	9540382	Aug 18, 2033			U-1650	
	9540382	Aug 18, 2033			U-1946	
	9540382	Aug 18, 2033			U-1947	
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034			U-2150	
	9801881	Jun 03, 2031			U-1491	
	9801883	Jun 03, 2031			U-2159	
	9814721	Jun 03, 2031			U-1947	
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
	>A> 8008309	Dec 28, 2026	DS DP			
	>A> 8476284	Dec 28, 2026			U-1456	
	>A> 8476284	Dec 28, 2026			U-1650	
	>A> 8476284	Dec 28, 2026			U-1946	
	>A> 8476284	Dec 28, 2026			U-1947	
	>A> 8476284	Dec 28, 2026			U-2241	
	>A> 8497277	Dec 28, 2026			U-1456	
	>A> 8497277	Dec 28, 2026			U-1491	
	>A> 8497277	Dec 28, 2026			U-1650	
	>A> 8497277	Dec 28, 2026			U-1946	
	>A> 8497277	Dec 28, 2026			U-1947	
	>A> 8497277	Dec 28, 2026			U-2241	
	>A> 8497277	Dec 28, 2026			U-2242	
	>A> 8563563	Apr 26, 2027			U-1491	
	>A> 8563563	Apr 26, 2027			U-1946	
	>A> 8563563	Apr 26, 2027			U-2241	
	>A> 8563563	Apr 26, 2027			U-2242	
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8703780	Dec 28, 2026			U-1491	
	>A> 8703780	Dec 28, 2026			U-2242	
	>A> 8735403	Dec 28, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 8754090	Jun 03, 2031	U-1456			
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 8999999	Jun 03, 2031	U-1491			
	>A> 8999999	Jun 03, 2031	U-1946			
	>A> 8999999	Jun 03, 2031	U-2241			
	>A> 8999999	Jun 03, 2031	U-2242			
	>A> 9125889	Jun 03, 2031	U-1650			
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9296753	Oct 30, 2033	DS			
	>A> 9655857	Mar 03, 2036	DP			
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9795604	Oct 24, 2034	U-2150			
	>A> 9801881	Jun 03, 2031	U-1491			
	>A> 9801881	Jun 03, 2031	U-2242			
	>A> 9801883	Jun 03, 2031	U-2159			
	>A> 9801883	Jun 03, 2031	U-2243			
	>A> 9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
	>A> 8008309	Dec 28, 2026	DS DP			
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8563563	Apr 26, 2027	U-1491			
	>A> 8563563	Apr 26, 2027	U-1946			
	>A> 8563563	Apr 26, 2027	U-2241			
	>A> 8563563	Apr 26, 2027	U-2242			
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8703780	Dec 28, 2026	U-1491			
	>A> 8703780	Dec 28, 2026	U-2242			
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8754090	Jun 03, 2031	U-1456			
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 8999999	Jun 03, 2031	U-1491			
	>A> 8999999	Jun 03, 2031	U-1946			
	>A> 8999999	Jun 03, 2031	U-2241			
	>A> 8999999	Jun 03, 2031	U-2242			
	>A> 9125889	Jun 03, 2031	U-1650			
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9296753	Oct 30, 2033	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 9655857	Mar 03, 2036	DP			
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9795604	Oct 24, 2034			U-2150	
	>A> 9801881	Jun 03, 2031			U-1491	
	>A> 9801881	Jun 03, 2031			U-2242	
	>A> 9801883	Jun 03, 2031			U-2159	
	>A> 9801883	Jun 03, 2031			U-2243	
	>A> 9814721	Jun 03, 2031			U-1947	
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	>A> 7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
	>A> 8008309	Dec 28, 2026	DS DP			
	>A> 8476284	Dec 28, 2026			U-1456	
	>A> 8476284	Dec 28, 2026			U-1650	
	>A> 8476284	Dec 28, 2026			U-1946	
	>A> 8476284	Dec 28, 2026			U-1947	
	>A> 8476284	Dec 28, 2026			U-2241	
	>A> 8497277	Dec 28, 2026			U-1456	
	>A> 8497277	Dec 28, 2026			U-1491	
	>A> 8497277	Dec 28, 2026			U-1650	
	>A> 8497277	Dec 28, 2026			U-1946	
	>A> 8497277	Dec 28, 2026			U-1947	
	>A> 8497277	Dec 28, 2026			U-2241	
	>A> 8497277	Dec 28, 2026			U-2242	
	>A> 8563563	Apr 26, 2027			U-1491	
	>A> 8563563	Apr 26, 2027			U-1946	
	>A> 8563563	Apr 26, 2027			U-2241	
	>A> 8563563	Apr 26, 2027			U-2242	
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8703780	Dec 28, 2026			U-1491	
	>A> 8703780	Dec 28, 2026			U-2242	
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8754090	Jun 03, 2031			U-1456	
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8952015	Dec 28, 2026			U-1456	
	>A> 8952015	Dec 28, 2026			U-1491	
	>A> 8952015	Dec 28, 2026			U-1650	
	>A> 8952015	Dec 28, 2026			U-1946	
	>A> 8952015	Dec 28, 2026			U-1947	
	>A> 8952015	Dec 28, 2026			U-2241	
	>A> 8952015	Dec 28, 2026			U-2242	
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 8999999	Jun 03, 2031			U-1491	
	>A> 8999999	Jun 03, 2031			U-1946	
	>A> 8999999	Jun 03, 2031			U-2241	
	>A> 8999999	Jun 03, 2031			U-2242	
	>A> 9125889	Jun 03, 2031			U-1650	
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9296753	Oct 30, 2033	DS			
	>A> 9655857	Mar 03, 2036	DP			
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9795604	Oct 24, 2034			U-2150	
	>A> 9801881	Jun 03, 2031			U-1491	
	>A> 9801881	Jun 03, 2031			U-2242	
	>A> 9801883	Jun 03, 2031			U-2159	
	>A> 9801883	Jun 03, 2031			U-2243	
	>A> 9814721	Jun 03, 2031			U-1947	
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	>A> 7514444	Dec 28, 2026	DS DP		>A> NCE	Nov 13, 2018
	>A> 8008309	Dec 28, 2026	DS DP			
	>A> 8476284	Dec 28, 2026			U-1456	
	>A> 8476284	Dec 28, 2026			U-1650	
	>A> 8476284	Dec 28, 2026			U-1946	
	>A> 8476284	Dec 28, 2026			U-1947	
	>A> 8476284	Dec 28, 2026			U-2241	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8563563	Apr 26, 2027	U-1491			
	>A> 8563563	Apr 26, 2027	U-1946			
	>A> 8563563	Apr 26, 2027	U-2241			
	>A> 8563563	Apr 26, 2027	U-2242			
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8703780	Dec 28, 2026	U-1491			
	>A> 8703780	Dec 28, 2026	U-2242			
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8754090	Jun 03, 2031	U-1456			
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 8999999	Jun 03, 2031	U-1491			
	>A> 8999999	Jun 03, 2031	U-1946			
	>A> 8999999	Jun 03, 2031	U-2241			
	>A> 8999999	Jun 03, 2031	U-2242			
	>A> 9125889	Jun 03, 2031	U-1650			
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9296753	Oct 30, 2033	DS			
	>A> 9655857	Mar 03, 2036	DP			
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9795604	Oct 24, 2034	U-2150			
	>A> 9801881	Jun 03, 2031	U-1491			
	>A> 9801881	Jun 03, 2031	U-2242			
	>A> 9801883	Jun 03, 2031	U-2159			
	>A> 9801883	Jun 03, 2031	U-2243			
	>A> 9814721	Jun 03, 2031	U-1947			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9861603	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9861603	Dec 18, 2026	U-1440			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	>A> 9884094	May 01, 2033	U-2238			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	>A> 8629162	Jun 24, 2025	U-2234			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	>A> 8629162	Jun 24, 2025	U-2234			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	>A> 8629162	Jun 24, 2025	U-2234			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	>A> 7495103	May 20, 2027	DS DP	>A> NCE		Feb 12, 2023
	>A> 7645789	May 01, 2027	DS DP			
	>A> 7776905	Jun 03, 2027	DS DP			
	>A> 8324242	Aug 05, 2027	U-2246			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	>A> 8410274	Dec 28, 2026	DP			
	>A> 8415387	Nov 12, 2027		U-2246		
	>A> 8598181	May 01, 2027		U-2246		
	>A> 8623905	May 01, 2027	DS DP			
	>A> 8629162	Jun 24, 2025		U-2247		
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 9012496	Jul 15, 2033		U-2248		
	>A> 9670163	Dec 28, 2026	DP	U-2246		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001					M-218	Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002					M-218	Jan 25, 2021
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001					>A> ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002					>A> ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001					>A> ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002					>A> ODE-165	Nov 08, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	>A> 9283174	May 10, 2031	DP		>A> NP	Feb 28, 2021
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	>A> 9890141	Oct 21, 2030	DS			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	9861622	Mar 07, 2025	U-1316			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001					>A> NPP	Feb 20, 2021
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE	Jan 26, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP U-2220			
	8192719	Oct 12, 2027	U-2220			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002 >A>	8323692	Mar 30, 2023	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9855215	Jan 02, 2033	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001 >A>	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002 >A>	9907793	Apr 04, 2023	DP U-1556			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001					D-170	Dec 22, 2020
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002					D-170	Dec 22, 2020
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001					I-762	Jan 12, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002					I-762	Jan 12, 2021
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2019	DS			
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001 >A>	8420674	Dec 18, 2027	U-2079			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003 >A>	8420674	Dec 18, 2027	U-2079			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001 >A>	9610321	Sep 15, 2031	U-1999		I-764	Jan 24, 2021
	>A> 9610321	Sep 15, 2031	U-2230			
<u>RIVAROXA BAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					NS	Jan 23, 2021
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002					NS	Jan 23, 2021
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	>A> 7828787	Oct 18, 2025	DP			
	>A> 7857802	Nov 28, 2026	DP			
	>A> 8118802	May 18, 2023	DP			
	>A> 8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	>A> 7828787	Oct 18, 2025	DP			
	>A> 7857802	Nov 28, 2026	DP			
	>A> 8118802	May 18, 2023	DP			
	>A> 8162915	May 23, 2024	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	9861638	Feb 10, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	9861638	Feb 10, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	9861638	Feb 10, 2031	U-2012			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9856265	Jul 28, 2026	DS DP U-1467			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9868745	Nov 16, 2032	DS DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001					>A> M-219 >A> PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 002					>A> M-219 >A> PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 003					>A> M-219 >A> PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 004					>A> M-219 >A> PED	Feb 15, 2021 Aug 15, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9855241	Jan 25, 2033	U-2149			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	>A> 7173038	Aug 14, 2021	DS DP			
	>A> 8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	>A> 7173038	Aug 14, 2021	DS DP			
	>A> 8642608	Feb 06, 2022	U-1490			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9861630	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm